A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With 
Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With 
an IDH2 Mutation 
John Mascarenhas, MD
[STUDY_ID_REMOVED]
Document Date: Nov 10, 2021
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2  Page 1 of 77 10 Nov 2021  
Confidential  
IND #:  144836  
IND Holder Name: John Mascarenhas, MD  
Funding Source :  NCI P01(funding)  
Investigational Product (IP):  Enasidenib (AG -221) 
IP Provider:  Celgene  
NCT#:  [STUDY_ID_REMOVED]  
Spons or/Investigator  
John Mascarenhas, MD  
Icahn School of Medicine at Mount  Sinai  
Tisch Cancer Institute,  
Division of Hematology/Oncology  
One Gustave L. Levy Place, Box 1079  
New York, New York 10029  
Tel: (212) 241- 3417  
Email: john.mascarenhas@mssm.edu  
Study Co -C hairs:  
Raajit  Rampal, MD PhD  
Memorial Sloan -Kettering Cancer Center  
1275 York Ave, Box 443 
New York, NY  10065  
Tel: (212) 639- 2194  
Fax: (212) -717-8550  
Email: rampalr@mskcc.org  Michal Bar -Natan , MD  
Icahn School of Medicine at Mount Sinai Division of Hematology/Oncology  
One Gustave L. Levy Place, Box 1079  
New York, NY  10029  
Tel: (212) 241- 6772  
Fax: (212) 876- 5276  
Email: michal.bar -natan@mssm.edu
 
Co-Investigator: Biostatistician  
Heidi Kosiorek, MS  
Mayo Clinic Cancer Center  
Division of Health Sciences Research  
13400 E. Shea Blvd Scottsdale, AZ, USA 85259  
Tel : (480) 301- 6415  
Email: Kosiorek.Heidi@mayo.edu
 
Statistics and Data Center Email: DLARZmpnrcstats@mayo.edu
 Co-Investigator: Pathologist  
Mohamad Salama, MD  
Mayo Medical Laboratories  
3050 Superior Drive NW  
Rochester, MN 55901- 1195  
Lab Phone: (507) 284- 1143  
Email: salama.mohamed@mayo.edu  
Co-Investigator: Biorepository  
Rona Singer Weinberg, PhD  
MPN -RC Tissue Bank  
New York Blood Center  
310 East 67th Street  
New York, NY  10065  
Tel: (212) 570 -3412  
Fax: (212)  570-3495  
Laboratory Tel: (212) 570- 3412  
Laboratory Fax: (212) 570- 3495  
Email: rweinberg@nybloodcenter.org  Ruben Mesa, MD  
Mays Cancer Center at UT Health  
San Antonio MD Anderson  
7979 Wurzbach Road San Antonio, Texas 78229  
Tel: (210) 450- 1406  
Fax: 210- 450-1100  
Email: mesar@uthscsa.edu  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2  Page 2 of 77 10 Nov 2021  
Confidential  
1.TRIAL CENTERS
Mayo Clinic – Arizona  
Jeanne Palmer, MD  
13400 E Shea Blvd.  
Scottsdale, AZ 85259 
Tel: (480) 301- 8335  
Fax:  (480) 301- 4675  
Email:  Palmer.Jeanne@mayo.edu  Icahn School of Medicine at Mount Sinai  
John Mascarenhas, MD  
One Gustave L. Levy Place, Box 1079  
New York, NY 10029  
Tel: (212) 241- 3417  
Fax: (212) 876- 5276  
Email: john.mascarenhas@mssm.edu  
Princess Margaret Cancer Centre  
Vikas Gupta, MD, FRCP, FRCPath  
610 University Avenue  
Toronto, Canada, M5G 2M9  
Tel: (416) 946 -4521  
Fax: (416) 946- 6546  
Email: vikas.gupta@uhn.ca  Wake Forest Baptist Health  
Rupali Roy Bhave, MD  
Medical Center Boulevard  
Winston -Salem, NC 27157  
Tel: (336) 716- 1808  
Fax: (336) 716- 5687  
Email: rbhave@wakehealth.edu  
Memorial Sloan -Kettering Cancer Center  
Raajit Rampal, MD, PhD  
1275 York Ave, Box 443 
New York, NY 10065  
Tel: (212) 639- 2194  
Fax: (212) 717- 8550  
Email: rampalr@mskcc.org  Cleveland Clinic – Taussig Cancer Center Institute  
Aaron Gerds, MD, MS  
2010 E 90th Street  
Cleveland, OH 44195  
Tel: (216) 445- 9840  
Fax: (216) 444- 9464  
Email: gerdsa@ccf.org  
Moffitt Cancer Center  
Andrew T. Kuykendall, MD  
Moffitt Cancer Center  
12902 Magnolia Drive  
Tampa, FL 33612  
Tel:  (813) 745- 6841  
Email: Andrew.Kuykendall@moffitt.org  Mays Cancer Center at UT Health San Antonio  
Ruben Mesa, MD  
7979 Wurzbach Road 
San Antonio, TX 78229  
Tel: (210) 450- 1406  
Fax: (210) 450- 1100  
Email: mesar@uthscsa.edu  
Roswell Park Comprehensive Cancer Center  
Amro Elshoury, MD  
Elm and Carlton Streets  
Buffalo, NY 14263  
Tel: (716) -845-6272  
Fax: (716) -845-3426  
Email: Amro.Elshoury@roswellpark.org  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 3 of 77   10 Nov 2021  
Confidential  
 
 
MPN -RC Clinical Consortium (Project 4)  John Mascarenhas, MD  
Icahn School of Medicine at Mount Sinai  
Division of Hematology/Oncology  
One Gustave L. Levy Place, Box 1079  
New York, NY  10029  
Tel: (212) 241- 3417  
Fax: (212) 876- 5276  
Email : john.mascarenhas@mssm.edu  
 
Ruben Mesa, MD  
Mays Cancer Center at UT Health San Antonio 
MD Anderson  
7979 Wurzbach Road 
San Antonio, TX 78229  
Tel: (210) 450-1406  
Fax: (210) 450-1100  
Email: mesar@uthscsa.edu  
 
MPN -RC Central Coordinating Office  Ronald Hoffman, MD  
Icahn School of Medicine at Mount Sinai  
One Gustave L. Levy Place, Box 1079  
New York, NY  10029  
Tel: (212) 241- 2297  
Fax: (212) 876- 5276  
Email : ronald.hoffman@mssm.edu  
 
Monitoring and Adverse Event Reporting  MPN -RC Data Monitor  
MPN -RC Central Coordinating Office  
Melissa Nashawati, MPA  
Tel: (210) 450- 3955  
nashawati@uthscsa.edu  
 
Statistics and Data Center Amylou  Dueck , PhD  
Mayo Clinic Cancer Center  
Division of Health Sciences Research  
13400 E. Shea Blvd 
Scottsdale, AZ, USA 85259  
Tel: (480) 301- 6159  
Email : Dueck.Amylou@mayo.edu  
Statistics and Data Center Email: DLARZmp nrcstats@mayo.edu
 
 
MPN -RC Tissue Bank  Rona Singer Weinberg, PhD  
New York Blood Center  
310 East 67th Street  
New York, NY 10065  
Tel: (212) 570- 3488  
Fax: (212) 570- 3495  
Laboratory Tel: (212) 570- 3412  
Laboratory Fax: (212) 570- 3495  
E-mail: rweinberg@nybloodcenter.org  
 
 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 4 of 77   10 Nov 2021  
Confidential  
 
TABLE OF CONTENTS  
1. TRIAL CENTERS  ........................................................................................ 2  
2. LIST OF ABBREVIATION S AND TERMS  ............................................. 8  
3. STUDY SCHEMA  ....................................................................................... 11 
4. STUDY SUMMARY ................................................................................... 12 
6. SCIENTIFIC  BACKGROUND AND  RATIONALE  ................................................................................ 15 
6.1 Disease Background  ..................................................................................................... 15  
6.2 RUXOLITNIB  .............................................................................................................. 17  
6.2.1  Clinical Experience in myelofibrosis with ruxolitinib  ........................................... 18  
6.3 Enasidenib (AG -221) ................................................................................................... 19  
7. STUDY  OBJECTIVES  ........................................................................................................................... 21 
7.1 Primary Objectives  ...................................................................................................... 21  
7.2 Secondary Objectives ................................................................................................... 22  
7.3 Exploratory Objectives ................................................................................................ 22  
8.0 PATIENT  ELIGIBILITY  .................................................................................................................. 22 
8.1 Inclus ion Criteria  ......................................................................................................... 22  
8.2 Exclusion Criteria  ........................................................................................................ 23  
9.0 SUBJECT RECRUITING  AND  SCREENING  ............................................................................. 24 
9.1 Study -wide recruitment methods  ............................................................................... 24  
10. TREATMENT DOSAGE AND ADMINISTRATION  .................................................................................... 24 
10.1  Dose Modification for non- hematological AE’s, clinically significant in the 
opinion of the treating physician  .......................................................................................... 25  
10.1.1  QT prolongation .................................................................................................... 25  
10.1.2   Abnormal Level of Liver Enzymes (Hyperbilirubinemia)  ............................... 26  
10.2  Dose modifications for hematological AE’s............................................................ 28  
10.3  Dose Escalations ........................................................................................................ 28  
10.4  Concomitant Medications/Treatments  ................................................................... 29  
10.5  IDH -Inhibitor Differentiation Syndrome (IDH -DS) ............................................. 29  
10.6  Non-infectious Leukocytosis  .................................................................................... 30  
10.7  Discontinuation of Ruxolitinib AND ENASIDENIB  ............................................. 30  
10.8  Evaluation During Treatment/Intervention  ........................................................... 30  
11. WHEN AND HOW TO WITHDRAW SUBJECTS  ....................................................................................... 30 
11.1  Data Collection and Follow- up for Withdrawn Subjects ...................................... 31  
11.2  DURATION OF FOLLOW -UP .............................................................................. 31  
11.3  Removal of Patients from Protocol Therapy ......................................................... 32  
11.4  Patient ACCRUAL  ................................................................................................... 32  
12.0 STUDY  TIMELINES  ......................................................................................................................... 32 
13.0 STUDY ENDPOINTS  ................................................................................................................................ 32 
13.1  Primary Endpoint  ..................................................................................................... 32  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 5 of 77   10 Nov 2021  
Confidential  
13.2  Secondary Endpoints  ................................................................................................ 32  
13.3  Safety Endpoints  ....................................................................................................... 33  
13.4  Exploratory Endpoints ............................................................................................. 33  
14.0 STUDY  PROCEDURES ..................................................................................................................... 33 
14.1  Screening/Baseline Procedures  ................................................................................ 33  
14.2  Registration Procedures  ........................................................................................... 34  
14.2.1   Site Registration with MPN -RC.......................................................................... 35  
14.3  Informed Consent  ..................................................................................................... 36  
14.4  Data Management..................................................................................................... 36  
15. TREATMENT PERIOD  ........................................................................................................................... 36 
15.1  End of Treatment visit  ............................................................................................. 37  
15.2  End of Study Visit  ..................................................................................................... 37  
16. ADVERSE EVENTS  ................................................................................................................................ 39 
16.1  Definitions OF ADVERSE EVENT  ........................................................................ 40  
16.2  SEVERITY OF ADVERSE EVENT  ...................................................................... 40  
16.2.1   SERIOUS ADVERSE EVENTs (SAE)  .............................................................. 40  
16.2.2   ADVERSE EVENTs OF SPECIAL INTEREST (AESI)  ................................. 41  
16.3  CAUSALITY ............................................................................................................. 41  
16.4  DURATION  .............................................................................................................. 42  
16.5  Action Taken  ............................................................................................................. 42  
16.6  Outcome  ..................................................................................................................... 42  
16.7  Overdose  .................................................................................................................... 42  
16.8  Abnormal Laboratory Values ................................................................................. 42  
17. REPORTING REQUIREMENTS FOR ADVERSE EVENTS  ......................................................................... 43 
17. 1  Steps to Determine if an Adverse Event Requires Expedited Reporting 
(WITHIN 24 hours)  ............................................................................................................... 43  
17.2  Expedited Reporting ................................................................................................. 43  
17.3  Reporting Guidelines for Pharmaceutical Partner  ............................................... 45  
17.4  MPN -RC Reporting of Suspected Unexpected Serious Adverse Reactions 
(SUSARs) to Regulatory Bodies and Ethics Committees  ................................................... 46  
17.5  MPN -RC Reporting of SUSARs  .............................................................................. 46  
17.6  Timelines for Reporting  ........................................................................................... 46  
17.7  How to Report Safety Events ................................................................................... 46  
18. DRUG  INFORMATION .................................................................................................................... 47 
18.1  RUXOLITINIB  ......................................................................................................... 47  
18.1.1   Side Effects  ............................................................................................................ 47  
18.2  Enasidenib  ................................................................................................................. 47  
18.2.1  Side Effects  ............................................................................................................. 47  
18.2.2   Study Drug Packaging and Labeling  .................................................................. 48  
18.2.3   Study Drug Storage .............................................................................................. 48  
18.2.4   Receiving Drug Supply, Receipt and Storage  .................................................... 48  
18.2.5   Return or Destruction of Study Drug  ................................................................. 48  
18.3  RISKS TO SUBJECTS  ............................................................................................ 48  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 6 of 77   10 Nov 2021  
Confidential  
18.3.1   Reproductive Risks  .............................................................................................. 49  
CORRELATIVES/  SPECIAL  STUDIES  ..................................................................................................... 49 
19.1  Shipping instructions  ................................................................................................ 49  
19.2  Bone Marrow Biopsy SLIDEs Guidelines  .............................................................. 50  
19.3  Bone Marrow Aspirate Guidelines  ......................................................................... 51  
19.4  Peripheral Blood: (use sterile technique)  ............................................................... 51  
19.5  Nail Clippings  ............................................................................................................ 51  
19.6  Cytogenetic Analysis ................................................................................................. 51  
19.6.1  General Inclusion Criteria for Conventional Cytogenetics  ............................... 52  
19.7  Specimen Banking  .................................................................................................... 52  
20. STATISTICAL  CONSIDERATIONS  .............................................................................................. 54 
STUDY DESIGN/STUDY E NDPOINTS  ....................................................... 54 
20.1  ACCELERATED / BLAST -PHASE COHORT  .................................................... 55  
20.1.2   POWER AND SIGNIFICANCE LEVEL / PRECISION  ................................. 55  
20.2  CHRONIC MPN PHASE  ........................................................................................ 55  
21. SAMPLE SIZE AND ACCRUAL  ............................................................................................................... 56 
22. DATA ANALYSIS PLANS  ....................................................................................................................... 56 
22.1  Primary endpoint  ...................................................................................................... 56  
22.2  Secondary Endpoints  ................................................................................................ 56  
22.3  Exploratory/Correlative Endpoints ........................................................................ 56  
23. STUDY  MANAGEMENT  .................................................................................................................. 57 
23.1  Conflic t of interest  .................................................................................................... 57  
23.2  Institutional Review Board (IRB) Approval and Consent  ................................... 57  
24. DATA MANAGEMENT AND MONITORING /AUDITING  .......................................................................... 57 
24.1  Data Monitoring Committee/Data Safety Monitoring Board (DMC/DSMB) .... 57  
24.2  Medical Monitoring  .................................................................................................. 58  
24.3  Monit oring Plan and Period of Observation .......................................................... 58  
25. REGULATORY REQUIREMENTS  ........................................................................................................... 58 
25.1  Adherence to the Protocol  ........................................................................................ 58  
25.2  Emergency Modifications  ........................................................................................ 58  
25.3  Other Reportable New Information and Protocol Deviations/Violations ........... 58  
25.4  Amendments to the Protocol  ................................................................................... 59  
25.5  Record Retention  ...................................................................................................... 59  
26. OBLIGATIONS OF INVESTIGATORS  ...................................................................................................... 59 
26.1  Good Clinical Practice .............................................................................................. 59  
26.2  Ethical Considerations ............................................................................................. 60  
26.3  Patient Information and Informed Consent  .......................................................... 60  
26.4  Patient Confidentiality  ............................................................................................. 60  
26.5  Protocol Compliance  ................................................................................................ 60  
26.6  Management of Information.................................................................................... 61  
26.7  Drug Accountability  ................................................................................................. 61  
26.8  Source Documents  .................................................................................................... 62  
26.9  Case Re port Forms (CRF)  ....................................................................................... 62  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 7 of 77   10 Nov 2021  
Confidential  
26.10  Premature Closure of the Study  .............................................................................. 63  
26.11  Record Retention  ...................................................................................................... 63  
26.12  Data  Management..................................................................................................... 63  
26.13  QUALITY ASSURANCE  ........................................................................................ 63  
27. WITHDRAWAL  OF SUBJECTS  ............................................................................................................ 64 
28. BREACH OF CONFIDENTIALITY  ............................................................................................................ 64 
29. POTENTIAL  BENEFITS  TO SUBJECTS  ....................................................................................... 64 
30. SHARING  OF RESULTS  WITH  SUBJECTS  ................................................................................. 64 
31. PRIOR  APPROVALS  ........................................................................................................................ 64 
32. ECONOMIC  BURDEN  TO SUBJECTS  .......................................................................................... 65 
33. CONSENT  PROCESS  ........................................................................................................................ 65 
34. REFERENCES  ................................................................................................................................... 66 
34.1  Appendix A: Response criteria  ................................................................................ 68  
34.2  Appendix B: IWG -MRT and ELN response criteria  ............................................ 69  
34.3  Appendix C:  Medications Known to Prolong the QT Interval  ........................... 70  
34.4  Appendix D:  Guidance IDH -Inhibitor Differentiation Syndrome (IDH -DS) 
Guidance for Management of Differentiation Syndrome in Subjects with Hematologic 
Malignancies Treatedwith IDH -inhibitors  .......................................................................... 71  
34.5  Appendix E:  Eastern Cooperative Oncology Group (ECOG) Performance 
Score Ratings  .......................................................................................................................... 74  
34.6  Appendix F: Myelofibrosis Symptom Assessment FORM (MF -SAF) V4.0........ 75  
34.7  Appendix G: New York Heart Association (NYHA) Class III or IV congestive 
heart failure ............................................................................................................................ 76  
34.8  Appendix H: FDA Medwatch Form  ....................................................................... 77  
 
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 8 of 77   10 Nov 2021  
Confidential  
LIST OF TABLES   
Table 1. Ruxolitinib initial dose for patients’ baseline platelet count by cohort ……27 
Table 2a. Ruxolitinib Dose Adjustment for patients with accelerated and blast phase 
MF for NON -HEMATOLOGICAL AEs ………………………………………………27 
Table 2b. Ruxolitinib Dose Adjustment for patients with chronic phase MF for thrombocytopenia or non-hematological AEs…………………………………………27 
Table 3a. Enasidenib Dose Adjustment for thrombocytopenia ………………………28 
Table 3b. Enasidenib Dose Adjustment for non-hematological AE………………….28 Table 4. Schedule of Events ……………………………………………………………..38 
Table 5. Correlative Studies Sample Collection Schedule…………………………….53 
Table 6. Statistical Power………………………………………………………………..55 
Table 7.  CRF Form Submission Schedule ……………………………………………..62
 
2. LIST OF ABBREVIATIONS AND TERMS  
AE adverse event  
AESI  adverse event of special interest  
ACS  acute coronary syndrome  
ALT  alanine aminotransferase (SGPT)  
AML  acute myelogenous leukemia  
ASCT  allogeneic stem cell transplantation  
AST  aspartate aminotransferase (SGOT)  
AUC  area under the plasma concentration -time curve  
BCRP  Breast Cancer Resistance Protein  
BID twice a day  
BM bone marrow  
BMF  bone marrow failure 
BUN blood urea nitrogen 
C Cycle  
CBC  complete blood count  
CBR  complete blast response  
CFR  Code of Federal Regulations  
CI clinical improvement  
CK creatine kinase  
Cmax  maximum (peak) concentration  
CRF  case report form  
CR complete response  
Cri complete response with incomplete recovery of counts  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events (Version 5 .0) 
C#D#  Cycle (number) Day (number)  
D, d day 
DEHP  di(2-ethylhexyl)phthalate  
EC Ethics Committee  
ECG  electrocardiogram  
ECHO  echocardiogram  
ECOG  Eastern Cooperative Oncology Group 
EDC  Electronic Data Capture  
EOS  end of study  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 9 of 77   10 Nov 2021  
Confidential  
2. LIST OF ABBREVIATIONS AND TERMS  
EOT  end of treatment  
ET  essential thrombocythemia  
FCBP  Female of child bearing potential 
FDA  Food and Drug Administration 
GCP  Good Clinical Practices  
GI gastrointestinal  
HIPAA Health Insurance Portability and Accountability Act  
HIV human immunodeficiency virus  
IB Investigator’s Brochure  
ICF informed consent form 
ICH International Conference on Harmonization  
IMRA                      Interval Milestone Response Assessment  
IND Investigational New Drug  
IP intraperitoneal  
IRB Institutional Review Board  
IV intravenous  
IWG/ELN  International Working Group/European Leukemia Net  
IWG -MRT  International Working Group for Myelofibrosis Research and treatment  
LVEF  left ventricular ejection fraction  
MF myelofibrosis  
MPN  myeloproliferative neoplasms  
MPN -RC Myeloproliferative Neoplasms Research Consortium  
MRI  magnetic resonance imagin g 
MUGA multi -grade acquisition  
NaCl  sodium chloride  
ORR  overall response rat e 
OS                           overall survival  
PB peripheral blood  
PBR  partial blast response  
PD progressive disease  
PI Principal Investigator  
PK pharmacokinetic  
PMF  primary myelofibrosis  
PO orally, by mouth  
PPHS  Program for the Protection of Human Subjects  
PR partial response  
PV polycythemia vera  
QD once a day  
QT ECG interval between onset of QRS complex to end of the T wave (QT interval)  
QTc QT interval corrected for heart r ate 
RBC  red blood cell  
SAE  serious adverse event  
SAF symptoms assessment form  
SUSAR  suspected unexpected serious adverse reaction  
Tmax  time to peak plasma concentration  
TSS total symptoms score  
ULN  upper limit of normal  
UPR/UPIRSO  Unanticipated problem involving risk to subjects or others  
US United States  
Vd volume of distribution  
Vol volume  
WBC  white blood cell  
 
 
 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 10 of 77   10 Nov 2021  
Confidential  
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 11 of 77   10 Nov 2021  
Confidential  
3. STUDY SCHEMA  
 
 
 
  

A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 12 of 77   10 Nov 2021  
Confidential  
4. STUDY SUMMARY  
Title  A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib  (AG-221) 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or 
Chronic -phase Myelofibrosis with an IDH2 Mutation  
Short Title  MPN -RC 119- The IDH2 Study  
Protocol Number  TBD  
Phase  Phase II  
Methodology  Open -label  
Study Duration  6 months; if response is met, subjects may enter the extension phase  indefinitely.  
Study Center(s)  Icahn School of Medicine at Mount Sinai, Mays Cancer Center at University of 
Texas San Antonio, Memorial Sloan -Kettering Cancer Center, Mayo 
Clinic -Arizona, Wake Forest Baptist Health, U niversity of Kansas Cancer Center, 
Moffitt  Cancer Center , University of Michigan, Cleveland Clinic Taussig Cancer 
Center Institute, Princess Margaret Cancer Centre , Cedars -Sinai Medical Center  
Objectives  Primary Objectives  
• To estimate the efficacy of ruxolitinib and enasidenib combination 
therapy in patients with accelerated -phase and blast -phase disease.  
Efficacy will be defined as the proportion of patients who achieve a best leukemia response of: complete response (CR), Partial Response (PR), 
compl ete response with incomplete recovery of counts (C Ri), as 
assessed by the modified 2013 International Working  Group (IWG) 
Response Criteria.  
Secondary Objectives  
• To assess the efficacy of the combination of ruxolitinib with enasidenib 
in patients with accelerated -phase and blast -phase disease using 
complete (CBR) and partial blast response (PBR).  
• To assess the efficacy (CR, PR, Clinical Improvement) of the combination of ruxolitinib with e nasidenib in patients with PMF, post -
PV MF, or post -ET MF in chronic phase and 4 -9% blasts as assessed by 
the modified 2013 International Working Group (IWG) Response Criteria  
• To determine the safety of the combination of ruxolitinib and e nasidenib 
based on the Common Terminology Criteria for Adverse Events version 5.0 (CT CAE).  
• To assess the impact of the combination of ruxolitinib with enasidenib 
on the overall survival (OS) of advanced phase MPN patients 
Exploratory Objectives  
• To determine the impact of the combination of ruxolitinib with enasidenib in patients with PMF, post- PV MF, or post -ET MF, on 
patient quality of life as assessed by Myelofibrosis  Symptom 
Assessment Form ( MF-SAFv4.0).  
• To evaluate the pharmacodynamics of ruxolitinib and enasidenib when combined in this population.  
• To eva luate the effects of combined therapy on gene expression and 
global methylation status.  
• To explore changes in mutant allele burden and clonal architecture of disease.  
 
Number of Subjects  32 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 13 of 77   10 Nov 2021  
Confidential  
Diagnosis and Main 
Inclusion Criteria  1. Subjects must be ≥ 18 years at the time of signing the Informed Consent 
Form (ICF).  
2. Understanding and voluntary signing an IRB -approved informed consent 
form.  
3. Diagnosis of:  
a. Accelerated -phase   (≥ 10% blasts in PB or BM) or blast -phase ( ≥ 20% 
blasts in PB or BM) myeloproliferative neoplasm (with history of prior 
myelofibrosis, polycythemia vera, or essential thrombocythemia)  
b. Previously treated patients with myelofibrosis with persistent disease 
or progressive disease (persistent or progressive splenomegaly, 
leukoc ytosis, anemia, or thrombocytopenia) with intermediate-1 or 
greater  risk disease accord ing to 2013 International Working Group 
(IWG) criteri a, and 4 -9% circulating blasts.  
4. Demonstration of an IDH2 mutation  
5. Platelet count >75,000X109/L for chronic phase myelofibrosis patients  
6. Prior therapy with either ruxolitinib or enasidenib is permitted, but not a 
combination of ruxolitinib and enasidenib.   
7. Patients with chronic phase myelofibrosis on ruxolitinib must be on the drug for at least 3 m onths and on a stable dose for at least one month.  
8. Subjects must have an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 to 2. ECOG 3 status will be allowed if attributable 
to MPN.  
9. Patients must have adequate organ function as demonstrate d by the 
following:  
a. Direct bilirubin < 2.0mg/dL, u nless due t o Gilbert’s disease or current 
elevations in  direct bilirubin associated with existing e nasidenib use.  
b. Serum creatinine < 2.0 mg/dL. 
c. A L T  a n d  A S T  ≤  3  x  u p p e r  l i m i t  o f  n o r m a l  ( u n l e s s  t r a n s a m i n i t i s  is considered to be related to  MF).  
10. Females of childbearing potential (FCBP) must have a negative serum or 
urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 – 14 
days prior to starting e nasidenib and must either commit to continued 
abstinence from heterosexual intercourse or begin TWO acceptable methods 
of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking 
enasidenib . FCBP must also agree to ongoing pregnancy testing. Men must 
agree to use a condom during sexual contact with a female of child bearing 
potential even if they have had a successful vasectomy. All patients must be 
counseled at a minimum of every 28 days about pregnancy precautions and 
risks of fetal exposure.  
11. All study participants must be able to swallow oral medication.  
12. Ability to adhere to the study visit schedule and all protocol requirements.  
 
Study Product(s), Dose, 
Route, Regimen  Ruxolitinib and e nasidenib will be given orally in 28 -day cycles.  Ruxolitinib dose 
will be given per protocol, en asidenib  will be given at 100 mg daily on enrollment 
for patients with accelerated and blast phase myelofibrosis regardless of platelet count. Patients with chronic phase myelofibrosis will receive e nasidenib at starting 
dose of 50mg daily for cycle 1. The dose of e nasidenib will be increased to 100mg 
for cycle 2 if the platelet count stays above  50,000 at the end of cycle 1 (Table 3 a) 
and no other therapy emergent SAE of grade >
2 developed (except grade 2 
hyperbilirubinemia that is acceptable for dose escalation).  
 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 14 of 77   10 Nov 2021  
Confidential  
Duration of administration  Duration of treatment anticipated to be at least 6 months.  Responders will 
continue therapy  indefinitely  unless progression of disease occurs, toxicity 
warranting discontinuation of therapy is observed, or at the discretion of the 
treating physician.  
Statistical Methodology  The primary endpoint of this study is best overall response, defined a s partial 
response or better (CR+PR+Cri), and will be defined as the best response by 
Cycle 6 of combination therapy.  All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response. Any  evaluable patient not meeting the definition for response will be 
deemed as having a non - response.  
 
The largest overall response rate where the proposed combination treatment regimen would be considered ineffective in this patient population is 5%, and the smallest response rate that would warrant subsequent studies with the proposed regimen is 25%. This is based on retrospective analysis applying the 2013 IWG Response Criteria to patients treated with ruxolitinib. A Simon’s two -stage 
minimax design will  be employed to test the null hypothesis that the true overall 
response rate in this patient population is at most 5%.  
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 15 of 77   10 Nov 2021  
Confidential  
6. SCIENTIFIC BACKGROUND  AND RATIONALE  
6.1 DISEASE BACKGROUND  
Myeloproliferative neoplasms  
Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are each 
clonal stem cell malignancies each of which are classified as Philadelphia chromosome negative 
myeloproliferative neoplasms (MPN) by the World Health Organization (WHO)2. A portion of patients 
with PV and ET ca n evolve to a clinical picture which resembles PMF (post - PV/ET MF). Post -PV/ET 
MF and PMF, collectively referred to as MF, have similar clinical phenotypes with a median age at 
diagnosis of 65 years3, 3,4. MF is characterized by severe constitutional symptoms, progressive 
hepatosplenomegaly, peripheral blood cytopenias often requiring transfusional support and a n increased 
propensity for transformation to a clinical picture resembling acute leukemia, termed myelofibrosis in blast phase (MF -BP)
5. Like chronic myeloid leukemia, the blast phase of the MPN is nearly always 
preceded by an accelerated phase (MF -AP). Patients with more than 10% blasts in the peripheral blood 
or bone marrow have a median survival of less than 12 months rendering such patients candidates for 
aggressive therapy and placing MF -AP squarely on the continuum of progression to blast phase (4.1). 
Approximately 10- 20% of MF patients will transform to MF- BP during the first decade following 
diagnosis with a median overall survival at the time of transformation of 2.6 months4,6.In addition, a 
recent publication report s that patient with 5 -9% of blasts  (≥ 4-9% PB or ≥ 5 -9% BM)  have similar  
inferior outcome as patients with > 10% blasts as compare to patient with <4% circulating blasts7. 
The choice of appropriate treatment options for MF patients  is currently based on the prognosis of the 
individual patient8. Several prognostic scoring systems that utilize various clinical parameters including 
age, leukocyte count, hemoglobin level, platelet count, monocyte count, peripheral blast count, presence 
of splenomegaly, constitutional symptoms and degree of bone marrow fibrosis (BMF) are helpful in 
predicting patient outcome4,9-11. Patients under the a ge of 65 without significant co -morbidities and 
intermediate/high risk disease by Lille classific ation or int-2/high risk by IWG -MRT PSS are considered 
candidates for reduced intensity conditioning stem cell transplant (RIC -SCT). Allogeneic stem cell 
transplant is the only modality that offers the potential for cure, although the risk of transplant related 
mortality (TRM) and the morbidity and mortality associated with graft versus host disease (GVHD) are 
considerable12. Patients old er than 65 or with competing co -morbidities are considered not to be 
candidates for RIC -ASCT but rat her candidates for therapies such as interferon -alfa, immunomodulatory 
agents (IMiDs) JAK2 -TKIs or histone deacetylase inhibitors (HDACI). MF patients that either fail 
current experimental therapies or are ineligible due to limiting cytopenias often have no alternative 
treatment options other than agents including hydroxyurea, melphalan, thalidomide, lenalidomide and 
danazol that achieve response rates of 20 -50%, but have not been shown to alter the natural progression 
of disease13,14.   
Activating mutations of the Janus Kinase 2 receptor tyrosine kinase (JAKV617F ), the thrombopoietin 
receptor (MPL W515L/K) and Calreticulin ( CALR )have been identified in many patients with MPNs. 
Approximately 50 -60% of patients with MF carry the JAK2 mutation s, 20 -25% CALR mutations and 
5% MPL mutations15-20. Mutations in additional Sex Combs -Like 1 (ASXL1), Ten -Eleven translocation -
2 (TET2), serine/arginine -rich splicing factor 2 (SRSF2), U2AF1 , IDH and others have also been 
discovered in MPN patients and can coexist independently of  JAK2V617F21-24.The prognostic 
significance of these mutations remains uncertain. Some  of the mutation are considered high risk 
mutations and confer worse OS25,26. Ruxolitini b (Small molecule inhibitor of JAK2) has  been shown to 
produce durable clinical benef its in terms of sp leen volume re duction and improvement in constitutiona l 
symptoms w ith an accep table toxicity profile27,28. Based on the resul ts of two phase III s tudies 
(COMFORT -I, COMFORT-II)27,28showing improvement in sp leen size, symptom cont rol and 
improvement in quali ty of life, rux olitinib  was approved for use i n pati ents w ith intermediate or high -risk 
myelofibrosis by the FDA. There i s also ev idence of a b enefit in overa ll surv ival (O S) in pat ients treat ed 
with ruxo litinib. An OS advan tage ( HR=0.58; 95% CI, 0.39 -0.85, p=0.0 05) in treated pat ients comp ared 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 16 of 77   10 Nov 2021  
Confidential  
to historical contro ls has been rep orted29.In addition, an ana lysis of the COMFORT- I study confirmed 
that patients treated w ith ruxolitini b had an OS advantage compared w ith placebo ( HR=0.58 , 95% CI, 
0.36- 0.95, p=0.03) w ith a me dian of 102 we eks of fo llow up30.Follow-up anal ysis of the COMFORT-II 
trial has a lso demonst rated an OS advan tage for patie nts treated with ruxo litinib31. 
In comparison to de novo AML, MPN -BP is highly resistant to standard induction chemotherapy and 
responses, if achieved, are difficult to maintain.  A retrospective review of 2333 myelofibrosis pat ients 
from Mayo clinic  identified 91 patients who met WHO criteria for MF -BP6. The median overall survival 
of the entire group was 2.6 months after leukemic transformatio n with a median survival of 3.9 months 
in those patients receiving AML -like inducti on therapy. No patient achieved a complete response (CR) 
with induction therapy.  In a retrospective study of 74 patients with BCR -ABL negative MPN -BP at the 
MD Anderson Cancer Center, the best outcomes were seen in those receiving allogeneic stem cell 
transplants either upfront or immediately after achieving a response to induction therapy32. The survival 
was the same (6 -7 months) for those patients that received either standard AML induction -like therapy 
or low dose therapies such as gemtuzumab, azacytidine or decitabine. In this review, a CR/CRi rate of 
46% was obtained with induction therapy but the median time to relapse was only 5 months. The 
prognosis for MPN -BP is dismal with present therapeutic options and more effective therapies are 
required. 
IDH2  Mutations in MPN:  The presence of IDH mutations has prognostic significance in patients with 
MPNs. IDH mutations are associated with an increased risk of leukemic transformation.  Co-occurring 
mutations in IDH1/2  and JAK2V617F33are associated with significantly reduced leukemia -free 
survival25in MF pati ents. Finally, IDH1/2 mutations are among the most frequently encountered events 
in MPNs that have progressed to AML33,34. These c linical observations suggest, as is the case with TET2 
mutations, that IDH mutations alter the disease biology of MPNs.  Moreover, a recent meta -analysis has 
showed that the presence of IDH mutation is associated with worse survival in patients with myelofibrosis
35. 
Preclinical Data: Development and characterization of a JaK2 V617F- Idh2R140Q murine model of 
MPN : To create a faithful model of phenotypic cooperativity betweenIDH2 andJAK2  mutations, 
conditional knock-in Idh2R140Q mice were crossed with Jak2 V617F and Mx1 -cre. Intraperitoneal 
injections of polyI:polyC were used to excise and induce expression of both mutant alleles in hematopoietic  cells.  Mice expressing combined  Idh2R140Q and Jak2 V617F demonstrated 
splenomegaly, leukocytosis and polycythemia similar to that of Jak2 V617F mice, at timed sacrifices at 
approximately 100 days. Histologically, these mice demonstrated disrupted splenic architecture with blast -like cells, not seen in Jak2 V617F mice. Bone marrow cytospins demonstrated abnormal myeloid 
elements with a strongly elevated M:E ratio. These data indicate that combined mutant mice have a lethal myeloproliferative neoplasm with histological pre -leukemic features. Competitive transplants 
demonstrated that the presence of the Idh2 mutant improved the competitive capacity of the donor bone 
marrow regardless of Jak2  mutant status. Transplant recipients developed a phenotype very similar to 
primary mice including polycy themia and thrombocytosis. Notably, leukocytosis was greater in 
recipients of Idh2R140Q- Jak2 V617F marrow in comparison to Jak2 V617F marrow. Flow cytometric 
analysis of Idh2 R140Q- Jak2 V617F primary mice demonstrated expansion of the lineage negative Sca+ 
cKit+ (LSK) population. Preclinical evaluation of combined JAK1/2 inhibition and IDH2 inhibition:  
To test the therapeutic efficacy of combined JAK1/2 inhibition and mutant IDH2 inhibition, Idh2R140Q- Jak2 V617F mice  were treated with ruxolitinib (60mg/kg) and e nasidenib  (100mg /kg) twice 
daily by gavage for 21 -28 days. Primary recipients of  Idh2R140Q- Jak2 V617F bone marrow treated with 
enasidenib  showed  reduction of plasma 2 -hydroxyglutarate (an oncometabolite product of mutant IDH2) 
to the level of wild type mic e (Figure 1A ). Monotherapy with either e nasidenib  or ruxolitinib  reduced 
splenomegaly, while combined treatment completely resolved splenomegaly ( Figure 1B ). Combined 
therapy with enasidenib  and ruxolitinib  normalized polycythemia and leukocytosis to a level not seen 
with monotherapy  (Figure 1C,D ).  In the spleen, cells identified morphologically as blasts are no longer 
present in single AG221 or combined treatment with AG221, but not  ruxolitinib , resulted i n reduction of 
CD34 immunohistochemical  staining in cells with megakaryocyte morphology ( Figure 1E, F ), 
transplant assay was used to examine the effect of therapy with inhibitors on donor chimerism. In 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 17 of 77   10 Nov 2021  
Confidential  
comparing peripheral blood from individual mice before  and after treatment, we observed that mice 
treated with either enasidenib or with combined enasidenib  and ruxolitinib  showed significant reductions 
in mutant donor chimerism; in contrast, mice treated with either ruxolitinib  or vehicle showed significant 
expansion of the proportion of mutant derived clones.  These effects were not seen in mice transplanted 
with Jak2 V617F- mutant cells demonstrating specificity for IDH2 -mutant MPN cells.  
Figure  1: Treatment of Idh2 R140Q Jak2 V617F combined mutant mice with combined JAK2 and 
IDH2 inhibitor:  
 
6.2 RUXOLITNIB  
JAKs play an i mportant role in signal transduc tion follow ing cytok ine and growth factor b inding to th eir 
receptors. In addit ion, J AKs activate a n umber of d ownstre am pathways implicated in the pro liferati on 
and survi val of mal ignant ce lls includi ng the S TATs (s ignal transducers and activators of t ranscr iption), 
a family of imp ortant latent transcr iption factors. Aberra nt activation of J AKs has been assoc iated with 
increa sed mali gnant ce ll pro liferati on and malignant cell survival in patien ts w ith Philadelphi a 
chromosome negati ve M PD.  The fi nding that per ipheral b lood from myelop roliferative d isease (MPD ) 
patients is capab le of form ing erythroi d and megakaryocyte co lonies in the absence of exogenous factors 
(which signal through J AKs) suggests that cells from these p atien ts are i ntrinsically different than normal 
cells.  In deed, work from a number of lab orator ies led to the ide ntificati on of mu ltiple somatic mutat ions 
in genes associ ated with cytok ine and growth factor s ignaling. Th ese include a mutat ion in the pseudo -
kinase domain of JAK2V617F (ami no acid 6 17, va line to pheny lalanine) that resu lts in const itutive 
activation of J AK2 and d ownstream STATs. Th is mutati on was fo und in > 90% of a ll PV patien ts and 
(A) 2HG 
quantification in plasma  
(B) Spleen we ights  
(C) Hematocrit levels  
(D)WBC count  
(E-F) representative 
images of  stained 
sections of spleen 
tissue.  
(F) CD34+ straining. 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 18 of 77   10 Nov 2021  
Confidential  
in approxi mate ly 50% of a ll ET and Mye lofibrosis with Mye loid Metap lasia (MMM) p atien ts. More 
recentl y, other mutati ons have been ide ntified in MPD patients lacking the J AK2V61 7F mutat ion. F or 
instance, ad ditional act ivating muta tions in JAK2, as we ll as a mutat ion in the thromb opoietin rece ptor 
(MPL) and ca lreticu lin (CALR) result in const itutive ligand- ind ependent JAK act ivation. Importantly, 
ectopi c express ion of each of these mutant ge nes has been d emonstrated to be suffic ient to cause MP N-
like syn dromes in mice.  Moreover, even i n MPN patien ts lacking a conf irmed J AK2 mutat ion, the 
detection of ST AT act ivation suggests dysregul ated JAK act ivity. In fac t, regard less of the mutat ional 
status of J AK2, the ma lignant ce lls expecte dly retain th eir respons iveness to  JA K act ivating cytoki nes 
and/or growth factors; hence, the y may b enefit from J AK inhibition . These f indings, in addition to the 
limited life span of the se patien ts and l ack of benef icial therapies for the trea tment of P MF and post -
PV/ET MF, c learly support the use of a J AK inhibitor in these d iseases.  
Ruxolitinib is a  JAK1/2 inhibitor that is currently FDA -approved for the treatment of patients with  
intermediate and high -risk MF (as well as PV patients with inadequate response to or are intolerant of  
hydroxyurea). Ruxolitinib is a substituted pyrrolopyrimidine  compound that acts as a potent and 
selective inhibitor of the Janus kinase family of enzymes. Ruxolitinib is a novel, potent, and selective 
inhibitor of the JAKs with modest selectivity for JAK2. Ruxolitinib potently (IC50 values < 5 nM) 
inhibits JAKs, yet  it does not significantly inhibit (<30% inhibition) a broad panel of 26 other kinases 
when tested at 200 nM  (approximately 100 times the average IC50 value for JAK enzyme inhibition). 
Moreover, in cell -based assays relevant to the pathogenesis of MPDs, su ch as JAK -STAT signaling and 
the growth of cytokine -dependent lines, ruxolitinib demonstrated excellent potency (IC50 values of 80-
141 nM). This  effect was not due to general cytotoxicity, because ruxolitinib (up to 25 μM) had no 
significant effect on the growth of cytokine -independent cell lines transformed by the Bcr -Abl  
oncogene.  In addition,  ruxolitinib inhibited JAK/STAT signaling and growth of a cell line expressing 
the JAK2 mutant variant (JAK2V617F) that has been implicated in the pathogenesis of the majority of 
Philadelphia chromosome  negative MPN. Additional details as to the  in vitro pharmacology of 
ruxoliti nib m ay be found in the Clinical Investigator’s  Brochur e (IB). Ruxolitini b was eval uated in two 
mouse model s wher e either a cytokine-dependen t multiple myeloma cell line, INA-6, orace ll line, BaF 3, 
engineered to express JAK2V617F was inoculated. The a bility of ruxoliti nib to inhibit JAK pathw ay 
signaling as well as tumor ce ll survival  and growth was assessed  in vi vo. In vi tro cell biology 
experim ents have demons trated that the potency  of ruxoliti nib is v ery s imilar b etween the cytokine-
dependent INA-6 myeloma cells, wi th wild type JAKs, and the BaF3 cells expressing a clinically 
relevant mutant JAK2. As such, the in vivo studies described herein char acterize the ability of 
ruxoliti nib to inhibit wild type JAK2 (using the INA-6 xen ograf t model) and MPD -related mutant JAK2 
(using a mouse model of sp lenom egaly driven by cell s expressing the mutant JAK2V617F) . 
Treatment of mice with orally  administ ered ruxoli tinib r esulted in a dose-dependen t suppression of 
STAT3 phosphoryl ation and tumor growth in the cytokine-dependent I NA-6 xenograft model at doses 
≥ 10mg/ kg BID. Moreov er, oral adminis tration of ruxoli tinib inhi bited the dramatic splenome galy in 
mice resulting from intravenous inocu lation of the BaF3-J AK2V617F cells. Addi tional detail s as to t he 
in vivo pharmacology of ruxoli tinib m ay be  found in the Clinical Investigator’s Brochure (CIB). In 
summary, pharm acological da ta obtained in both in vitro and i n vi vo model  systems support the potenti al 
utility of ora lly administ ered ruxo litinib in t he treatment of ma lignanc ies, inclu ding MPD such as  PMF 
and P ost-PV/ET M F. 
The che mical n ame of ruxoli tinib phosphate is  (R)-3-(4-(7H -pyrrolo[2,3- d] pyrimidin-4-yl)-1H -
pyrazol-1-yl)-3-cyclopentylpropaneni trile phospha te. Ruxolit inib phosphate has a molecular for mula 
of C17H21N6O4P and a molecular weight of 404. 36. Ruxolit inib phosphate  drug subs tance is a whi te 
to off -white powder and  is referred to herein as ruxolitinib. 
6.2.1 CLINICAL EXPERIENCE IN MYELOFIBROSI S WITH 
RUXOLITINIB  
 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 19 of 77   10 Nov 2021  
Confidential  
Ruxolitinib has  been shown to produ ce durable clinical benef its in terms of sp leen volume re duction and 
improvement in constitutional symptoms with an acceptable toxicity profile27,28. Based on the results of 
two P hase III studies (COMFOR T-I, COMFORT-II)27,28 showing improv ement in spleen siz e, symptom 
control and improv ement in quali ty of life, ruxo litinib w as appro ved for use in patients with i ntermediate 
or high-risk myelofibrosis by the FDA. There is al so evide nce of a benefit in ov erall survival (OS) in 
patients treated with ruxolitinib. An OS advantage ( HR=0.58; 95% CI, 0.39-0.8 5, p=0.005)  in treat ed 
pa
tients compar ed to hist orical  controls has been  repo rted29. In addition, an analysis of t he COMFORT-
I study confirm ed that patie nts treated with ruxo litinib had an OS advantage compared  with plac ebo 
(HR=0.58,95%CI, 0.36-0.95, p-0.03) with a median of 102 weeks o f followup30. Follow-up analysis of 
the COMFO RT-II trial has al so demonstr ated an OS advantage for patie nts treat ed with ruxo litinib31. 
6.3 Enasidenib (AG -221)  
The IDH enzymes play critical roles in catalyzing the oxidative decarboxylation of isocitrate to produce 
carbon dioxide (CO2) and alpha -ketoglutarate (α -KG) enzyme in the citric acid cycle.  Of the two best 
characterized isoforms, IDH1 and IDH2, mutations in IDH2 have been found in approximately 15% of  
subjects with AML36,37.  The mutated proteins have a gain -of-function, neomorphic activity, catalyzing 
the reduction of α -KG to 2-HG while lacking the ability to synthesize isocitrate38.  The excess 
accumulation of 2- HG le ads to inhibition of dioxygenase dependent enzymes such as ten- eleven 
translocation (TET) and Jumonji which are responsible for demethylating DNA and histones, 
respectively, the consequence of which results in an altered epigenetic state and impaired cellu lar 
differentiation39,40.   
Recurring mutations in IDH2 may be important for AML pathogenesis or disease progression41.  
Retrospective clinical data have revealed that the presence of IDH1 mutations is associated with a worse 
prognosis in younger cytogenetically- normal AML subjects and subjects with IDH2 mutations had a 
significantly lower complete response rate37.  In a retrospective study of 398 subje cts <  60 years of age 
who were diagnosed with AML and randomly assigned to rece ive induction therapy with high- dose or 
standard dose daunorubicin, IDH2 mutations were in general associated with an improved overall 
survival42.  Prospective clinical studies will help further understand the impact mutations, co -mutations, 
and/or karyotype status have on disease outcomes in the presence of an IDH mutation.  
Enasidenib  is a first -in-class, selective, potent inhibitor of the neomorphic activity of IDH2 mutant 
enzyme and has been shown to suppress 2- HG production in enzymatic, cell -based, and in vivo systems.  
Pharmacology studies support that suppression of 2- HG levels by  enasidenib  results in alterations of 
cellular downstream markers, leading to a release in the block of tumor cell differentiation.  
Enasidenib  has rapid oral absorption, low to medium total body plasma clearance, and low to high 
volume of distribution. The  half-lives range from 2.5 to  5.4 hours, and oral bioavailability was 
approximately 40% to 50% (free base) in toxicology species.  Enasidenib is metabolized by multiple 
cytochromes (CYPs) and uridine diphosphate (UDP) -glucuronosyl transferases (UGTs).  Ena sidenib  is 
a direct inhibitor for CYP2C8,2C9, 2C19 and 2D6, as well as UDP -glucuronosyl transferase 1 family, 
polypeptide A1 (UGT1A1). The N -dealkylated metabolite, AGI -16903 is also an inhibitor of CYP1A2, 
2C8 and 2C9.  Enasidenib and AGI -16903 are weak inducers of CYP3A4.  Preliminary results indicate 
that enasidenib increased 4β- hydroxycholesterol level in subjects, indicating CYP3A induction in 
patients.  Enasidenib is not a substrate, but is a potent inhibitor of P -glycoprotein (P -gp) and breast 
cancer  resistance protein (BCRP).  In vitro, e nasidenib  is an inhibitor of organic anion transporter 
(OAT) 1, OATP1B1, OATP1B3, and organic cation transporter (OCT) 2, while AGI -16903 is an 
inhibitor of BCRP, OAT1, OAT3, OATP1B1, and OCT2.  AGI -16903 is also a substrate of P -gp and 
BCRP.  Clinical relevance of such in vitro interactions will be evaluated in humans as needed.  
The toxicity profile of enasidenib has been evaluated in repeat dose oral toxicity studies of up to 90 days 
in Sprague -Dawley rats, and cyn omolgus monkeys and for 7 days in beagle dogs, and in the bacterial 
reverse mutation (Ames) and mammalian chromosomal aberration assays in vitro.  Enasidenib  was 
neither mutagenic nor clastogenic.  Dose -limiting toxicities in rats after 28  days of dosing w ere 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 20 of 77   10 Nov 2021  
Confidential  
multifactorial and included gastrointestinal tract atrophy and erosions, lymphoid atrophy, degeneration, 
and necrosis, bone marrow hypocellularity and necrosis, skeletal muscle degeneration and necrosis, 
pancreas and kidney epithelial vacuolation, and adrenal cortical hemorrhage and necrosis.  After 
90 days of dosing, non- dosing limiting target organ toxicities in rats were limited to testes/epididymides 
and pancreas.  In monkeys, ulcerative inflammation in the large intestine was determined as the dose-limiting toxicity.  No changes in cardiovascular functions were noted in monkeys; however coronary 
artery lesion (periarteritis) was observed at the dose associated with dose- limiting toxicity indicated 
above.  Findings in large intestine and coronary artery in monkeys were observed following 28 days of 
dosing.  Additional target organ toxicities secondary to decreased body weight and food consumption 
in monkeys included femur/tibia (either dysplasia or decreased thickness of physis), bone marrow 
(decreased cellularity), thymus (atrophy/involution), liver (cytoplasmic rarefaction) and pancreas 
(acinar cell degranulation).  In dogs, there were enasidenib dose -related prolonged heart rate- corrected 
QT (QTc) intervals, hypotension and increased heart rate.  Th ese functional cardiovascular effects of 
enasidenib were the likely underlying causes of coronary artery lesions in dogs.   
As of 15 Apr 2016, data are available for 330 subjects from Study AG221 -C-001 who have been 
administered enasidenib across 13 dosing  cohorts up to a 650 mg daily dose, including both BID and 
QD dosing regimens.  Study AG221 -C-002, a food effect study in healthy volunteers is complete. Study 
AG-221- CP-001, a pharmacokinetic (PK) and safety study in healthy male Japanese and Caucasian 
adult subjects, and Study AG -221- CP-002, a PK study to evaluate the metabolism and excretion and 
determine absolute bioavailability of enasidenib in healthy male adult subjects, are also complete.  
Study AG221 -C-003, a Phase 1/2 dose escalation study, evalua ted enasidenib at doses ≥ 100 mg daily 
in subjects with advanced solid tumors with an IDH2 mutation, including glioma, and in subjects with AITL with an IDH2 mutation. Doses up to 650 mg were well -tolerated. The expansion phase of AG221-
C-003 was canceled based on the S ponsor’s decision to focus on the relapsed refractory AML indication 
and not for any safety reason. Ongoing studies include a Phase 3 randomized study in subjects with R/R AML with IDH2 mutation (AG-221- AML -004), a Phase 1b/2 study in subject s with newly -diagnosed 
AML (AG-221- AML -005), and a Phase 1 study in subjects with newly diagnosed AML sponsored by 
Agios in collaboration with Celgene (AG120-221-C- 001).  Study AG -221-C- 005 is evaluating oral AG -
120 plus subcutaneous (SC) azacitidine and oral enasidenib plus SC azacitidine in subjects with newly diagnosed AML with IDH1 or IDH2 mutation, respectively, who are not candidates to receive intensive induction chemotherapy. Study AG120 -221-C- 001 is evaluating AG -120 or enasidenib in combination 
with induction and consolidation therapy in subjects with newly diagnosed AML with an IDH1 and/or 
IDH2 mutation.  
Data from Study AG221 -C-001 showed that enasidenib was well -tolerated at total daily doses up to 650 
mg. The MTD was not reached in the dose escalation part of the AG221-C- 001 study. Based on  
pharmacodynamic and efficacy data, the 100 mg daily dose was chosen for further development.  No 
meaningful differences in nature, incidence, or severity of the Adverse Events ( AE) have been observed 
betwe en subjects with R/R AML, previously untreated AML, or MDS. As of 15 Apr 2016, 93 deaths 
have been reported in Study AG221 -C-001 either on study or within 28 days of the last dose of study 
treatment.  Deaths were attributed to complications of the underlying condition or disease prog ression, 
with an exception of 1 subject who experienced pericardial effusion complicated by fatal cardiac 
tamponade. Retrospective analysis of this case suggests that pericardial effusion was a likely sign of isocitrate dehydrog enase- differentiation syndrome (IDH -DS).  Serious adverse events (SAEs) reported 
in ≥ 5% of the study participants included febrile neutropenia in 79 (23.9%), pneumonia in 47 (14.2%), sepsis in 39 (11.8%), pyrexia in 28 (8.5%), leukocytosis in 27 (8.2%), I DH-DS in 24 (7.3%), lung 
infection in 21 (6.4%), acute renal failure in 18 (5.5%), tumor lysis syndrome (TLS) in 18 (5.5%), and 
fatigue in 17 (5.2%) subjects. 
The safety and tolerability of enasidenib has been evaluated in more than 440 subjects enrolled i n 
clinical studies of subjects with hematologic malignancies or solid tumors and single -dose 
pharmacology studies in healthy volunteers, as of the data cutoff date for this IB (15 Apr 2016 for Study 
AG221 -C-001 and 01 Jul 2016 for all other ongoing clinica l studies).  In clinical studies, enasidenib 
overall was generally well tolerated, with a relatively low incidence of discontinuations due to AEs.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 21 of 77   10 Nov 2021  
Confidential  
Specific adverse drug reactions (ADRs) to enasidenib were identified. Events of IDH -DS (similar to a 
syndrom e observed with retinoic acid in acute promyelocytic leukemia), noninfectious leukocytosis, 
TLS, GI disturbances (such as nausea, diarrhea, vomiting, and associated dysgeusia and decreased 
appetite), and hyperbilirubinemia have been observed in subjects with hematologic malignancies. 
Gastrointestinal disturbances and hyperbilirubinemia have been also observed in subjects with solid 
tumors. IDH -DS and noninfectious leukocytosis are associated with enasidenib mechanism of action 
and generally decrease in incidence with time.  
Preliminary analysis of PK data in Study AG221 -C-001 (as of 15 Apr 2016) from subjects with 
advanced hematologic malignancies up to the 650 mg QD dose level demonstrated high plasma 
exposures, a long mean plasma half -life of enasidenib aft er a single dose, high drug accumulation after 
multiple doses, and relatively high PK variability.  The mean time to Cmax (Tmax) ranged from approximately 1 to 24 hours when administered as a single dose 3 days before study treatment began.  
In a subset of  IDH2 mutated AML subjects, correlation of drug exposure, 2- HG levels, and IDH2 
mutation site was evaluated.  A comparison of PK data between the 2 groups (R140Q and R172K) at 
the enasidenib 100- mg dose level indicated that the average steady state exposur e level (AUC0 -10 or 
Cmax) was similar. Enasidenib treatment decreased 2 -HG levels in R140Q and R172K patients.  
Preliminary analysis showed no clear correlation between 2 -HG suppression and clinical response to 
enasidenib. 
As of 15 Apr 2016 in Study AG221 -C-001, the overall response rate (ORR) (defined as complete 
response [CR] + CR with incomplete neutrophil recovery [CRi] + morphologic CR with incomplete 
platelet recovery [CRp] + partial response [PR] + marrow CR [mCR] + morphologic leukemia free state 
[MLFS]) among the 113 subjects in the dose escalation phase was 45.1% with a median time to first 
response of 1.9 months and a median time to best response of 3.7 months.  Twenty -four of the 113 
subjects (21.2%) achieved a best response of CR, with a median time to CR of 3.8 months. Responses 
occurred in all dosing groups (30 mg BID to 650 mg QD). Of the 176 subjects with R/R AML in the combined Phase 1 part of the study, the ORR was 40.3%, with a median duration of response of 5.8 
months.  Thirty -four of the  176 subjects (19.3%) achieved a CR, with a median duration of CR of 8.8 
months. The ORR, CR, and median duration of response were similar in the subset of subjects who received the 100 mg daily dose compared with the total R/R AML population. Of the 71 re sponders 
among subjects with R/R AML, the median  time to first response was 1.9 months and the median time 
to best response was 3.7 months.  The median times to first response and best response were similar in the subset of subjects who received the 100 mg  daily dose.  At the time of data cutoff, median event -
free survival for subjects with R /R AML was 6.4 months (95%  CI = 5.4, 7.5) and median overall 
survival was 9.3 months (95% CI = 8.2, 10.9). 
This study
43 led to the Food and Drug Administration approval to enasidenib for the treatment of adult 
patients with relapsed or refractory acute myeloid leukemia with IDH2 mutation in August 2017.  
Please refer to the current version of the enasidenib IB for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and AE profiles of enasidenib . 
7. STUDY OBJECTIVES  
Ruxolitini b (also kn own as I NCB 018424 ), a J AK1/2 inhibi tor, and enasidenib (AG -221, an IDH2 
inhibitor) are  effective and tol erable treatments for patien ts with mye lofibros is (MF) and acute myeloid 
leukemia (AML), respectively. We hyp othesize th at the comb ination of these agent s in pati ents w ith 
MPN with an IDH2 mutation w ill improve the overa ll clinical response to therapy w ithout caus ing 
excessi ve tox icity. 
7.1 PRIMARY OBJECTIVES  
• To estimate the efficacy of ruxolitinib and enasidenib  combination therapy in patients with 
accelerated -phase and blast -phase disease.  Efficacy will be defined as the proportion of patients 
who achieve a best leukemia response of: complete response (CR), Partial Response (PR), 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 22 of 77   10 Nov 2021  
Confidential  
complete response with incomplete recovery of counts (Cri), as assessed by the modified 2013 
International Working Group (IWG) Response Criteria.  
7.2 SECONDARY OBJECTIVES  
• To assess the efficacy of the combination of ruxolitinib with enasidenib in patients with 
accelerated -phase and blast -phase disease using complete (CBR) and partial b last response 
(PBR).  
• To assess the efficacy (CR, PR, C linical Improvement ) of the combination of ruxolitinib with 
enasidenib in patients with PMF, post -PV MF, or post -ET MF in chronic phase and 4- 9% bla sts 
as assessed by the modified 2013 International Working Group (IWG) Response Criteria  
• To determine the safety of the combination of ruxolitinib and enasidenib based on the Common 
Terminology Criteria for  Adverse Events version 5.0 ( CTCAE ). 
• To assess th e impact of the combination of ruxolitinib with enasidenib on the overall survival of 
advanced phase MPN patients.  
7.3 EXPLORATORY OBJECTIV ES 
• To determine the impact of the combination of ruxolitinib with enasidenib in patients with PMF, 
post- PV MF, or post-ET MF, on patient quality of life as assessed by the Myelofibrosis Symptom 
Assessment Form (MF -SAFv4.0). 
• To evaluate the pharmacodynamics of ruxolitinib and enasidenib when combined in this 
population. 
• To evaluate the effects of combined therapy on gene expression and global methylation status.  
• To explore changes in mutant allele burden and clonal architecture of disease.  
8.0 PATIENT ELIGIBILITY  
Eligibility waivers are not permitted. Subjects must meet all of the inclusion and not meet any of the exclusion criteria to be registered to the study by the Central Office. Study treatment may not begin 
until a subject is registered.  
8.1 INCLUSION CRITERIA  
1. Willing and able to adhere to the study visit schedule and all protocol requirements  
2. Subjects must be  ≥ 18 years at the time of signi ng the  Informed C onsent  Form (ICF) . 
3. Diagnosis of: 
a. Accelerated -phase ( ≥ 10% blasts  in PB or BM ) or blast -phase ( ≥ 20% blasts in PB or BM ) 
myeloproliferative neoplasm (with history of prior myelofibrosis, polycythemia vera, or essential 
thrombocythemia)  
b. Previously treated patients with myelofibrosis with persistent disease or progressive disease (persistent or progressive splenomegaly, leukocytosis, anemia, or thrombocytopenia) with intermediate-1 or greater  risk disease accord ing to 2013 International Working Gr oup (IWG) 
criteri a, and 4-9% circulating blasts.  
4. Demonstration of an IDH2 mutation . 
5. Platelet  count   > 75,000  X 109/L for chronic phase myelofibrosis  patients . 
6. Prior therapy with either ruxolitinib or e nasidenib  is permitted, but not a combination of ruxolitinib 
and enasidenib .   
7. Patients with chronic phase myelofibrosis on ruxolitinib must be on the drug for at least  3 months 
and on a stable dose for a t least one  month. 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 23 of 77   10 Nov 2021  
Confidential  
8. Subjects must have an Eastern Cooperative Oncology Group ( ECO G) pe rformance status of 0 to 2. 
ECOG 3 status will be allowed if attributable to MPN.  
9. Patients must have ad equate organ funct ion as  demonstrated by the fol lowing: 
a. Direct bilirubin < 2.0mg/dL, unl ess due t o Gilbert’s di sease or current elevations in  direct 
bilirubin associated with existing enasidenib use. 
b. Serum cre atinine< 2.0 mg/ dL. 
c. ALT and AST ≤ 3x upper  limit o f normal (unle ss transami nitis is con sidered to be related 
to MF ). 
10. Fema les of ch ildbeari ng pote ntial (FCBP) must have a negative serum or uri ne pregn ancy test w ith 
a sens itivity of at l east 50 m IU/mL within 10 – 14 days prior  to start ing enasidenib  and must 
either commi t to continued abst inence from h eterosexual intercourse or beg in TWO accept able 
methods of bi rth co ntrol, one hi ghly effect ive method and one a dditional effective method AT  
THE SAME TIM E, at lea st 4 weeks before she starts tak ing enasidenib . FCBP must a lso agree 
to ongoi ng pregna ncy test ing. Men must a gree to use a condom duri ng sexual con tact w ith a fema le 
of ch ild bearing po tential even if th ey have had a successful vasectomy. Al l patien ts must be 
counse led at a m inimum of every 28 days about pregn ancy preca utions and r isks of fetal exposure.  
11. All study participants must be a ble to swa llow oral me dication.  
8.2 EXCLUSION CRITERIA  
1. Use of any other standard anti -neoplastic drug or growth factor (e.g., anagrelide, G -CSF, 
lenalidomide, thalidomide clofarabine) except hydroxyurea or experimental drugs, with the 
exception of r uxolitinib or  enasidenib , less than 14 days or 5 -half-lives, whichever is longer, prior 
to starting study therapy and/or lack of recovery from all toxicity (except for alopecia)  from 
previous therapy to Grade 1 or better. 
a. Patients will be pe rmitted to r eceive hydroxyurea while on s tudy for up to a total of 3 cycles 
of combined therapy. 
2. Known pri or clinically relevant hypersens itivity reaction to ruxolitinib or  enasidenib. 
3. Prior therapy w ith enasidenib  in comb ination wi th ruxo litinib. 
4. Concurrent use of strong inducers of CYP3A4 (Rifampin, St. John’s Wort, Carbamazepine,   Phenytoin) and/or the following strong inhibitors of CYP3A4 (protease 
inhibitor containing HIV anti -retrovirals , cobicistat, clarithromycin, itraconazole, ketoconazole, 
nefazodone , and telithromycin) are prohibited.  Also prohibited are CYP2C9 substrate 
medications that have a narrow therapeutic range: phenytoin and warfarin
. 
5. Any seri ous me dical cond ition, lab oratory a bnorma lity, or psychi atric illness th at wou ld prevent 
the subject from signing the inf ormed consent form, whi ch places the subject at unaccep table risk 
if he/she w ere to pa rticipate in t he study or whi ch co nfounds the a bility to i nterpret data from the 
study. 
6. Lactat ing fema les. 
7. Active uncontrolled infections . 
8. Patients with act ive ma lignancy of other type tha n requi red for th is study are not  eligible with the 
exception of curre ntly treated basal cell , squamous ce ll carcinoma of the sk in, or carc inoma " in 
situ" of the cerv ix or breast. P atients w ith ma lignanci es with indolen t behav ior such as  prostate 
cancer treated w ith ra diation or surgery can be e nrolled in the study as long as they have a 
reasonab le expectati on to have been cured with the  treatment modality recei ved. 
9. Subject has significant active cardiac disease within 6 months prior to the start of study treatment, 
in
cluding New York Heart Association (NYHA) C lass III or IV congestive heart failure (Appendix 
G) acute coronary syndrome (ACS); and/or stroke; or left ventricular ejection fraction (LVEF) < 
40% by echocardiogram (ECHO) or multi -gated acquisition (MUGA) scan obtained within 
28 days prior to the start of study treatment. 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 24 of 77   10 Nov 2021  
Confidential  
10. QTc interval (Fridericia’s correction [QTcF]) > 450 ms  
All inclusion and exclusion criteria will be reviewed by the Investigator or qualified designee to 
ensure that the patient qualifies for the trial.  
9.0 SUBJECT RECRUITING AND SCREENING  
Patients will be recruited from the sites p articipating in the MPN -RC. It is expected that a maximum of 
32 patients will be recruited to this study. The estimated accrual rate is 2 -3 patients per month. 
9.1 STUDY -WIDE RECRUITME NT METHODS  
Potential research subjects will be identified by a member of  the patient’s treatment or research teams. 
If the Investigator is a member of the treatment team, s/he will screen their patient’s medical records for suitable research study participants and discuss the study and their potential for enrolling in the 
research study. Potential subjects contacted by their treating physician will be referred to the 
Investigator/research staff of the study. The extent of the risks, benefits, toxicities/side effects, 
alternatives/options for treatment, financial costs/burdens, and the voluntary nature of the study will 
be explained to patients. All patients will be required to sign a written informed consent prior to being registered on this protocol. Every effort will be made to answer questions raised by patients and their 
families or advocates regarding the protocol and alternative therapies prior to asking a patient to sign 
the consent form. 
Patients of all races, both male and female, will be accepted into the protocol.  
10. TREATMENT DOSAGE AND ADMINISTRATION  
Patients who ar e on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib  
will receive ruxolitinib per Table 1 dosing based on platelet count (modified package insert dosing) . 
Enasidenib  will be given at 100 mg daily on enrollment for patients with accelerated and blast phase 
myelofibrosis regardless of platelet count (this will be deemed C ycle 1). Patients with chronic phase 
myelofibrosis will receive Enasidenib at starting dose of 50  mg daily for cycle 1. The dose of 
Enasidenib  will be increased to 100 mg for cycle 2 if the platelet  count stays above 50,000 at the end 
of cycle 1  (Table 3a) and no other therapy emergent S AE of grade > 2 developed (except grade 2 
hyperbilirubinemia that is acceptable for dose escalation) . 
Ruxolitinib and enasidenib will be given orally in an outpatient setting unless the patient is being seen 
inpatient for another reason. Ruxolitinib and enasidenib will be given orally in 28- day cycles.  
Patients should fast 2 hours before and 1-hour post enasidenib . Ruxolitinib may be administered 
independent of fasting and may be given with enasidenib . All protocol mandated visits will be 
performed at one of the participating institutions. Patients will return to the treating institution at a 
minimum of weekly during Cycles 1 and 2, every 4 weeks  for Cycles 3 and beyond. Additional  clinic 
visits will be mandated according to the patient clinical condition and at the discretion of the treating provider. Patients will have an end of study visit for a safety follow -up at 30 days after their last dose 
of therapy. 
The dosages of ruxolitinib and/or enasidenib can be reduced, based on assessment of adverse events, 
if any occur, as described below in Section 10.1. Missed or vomited doses of ruxolitinib or enasidenib 
will not be made up. 
Twenty -eight days is considered one cycle of therapy. Attempts will be made to provide an adequate 
treatment period with the combination of at least 6 cycles , unless significant toxicity is observed, to 
account for delayed time to response obs erved with biologic agents. Responders will continue therapy 
indefinitely unless progression of disease occurs, toxicity warranting discontinuation of therapy is 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 25 of 77   10 Nov 2021  
Confidential  
observed, or at the discretion of the treating physician. Patients will  have an end of study v isit for a 
safety follow- up at 30 days after their last dose of therapy.  
10.1  DOSE MODIFICATION FO R NON -HEMATOLOGICAL AE’S, 
CLINICALLY SIGNIFICANT IN THE OPINION OF  THE TREATING 
PHYSICIAN  
Based on available pharmacokinetic and drug metabolism data, r uxolitinib is mainly metabolized by 
CYP3A4 with additional contribution from CYP2C9. Enasidenib inhibits CYP 2C9 and induces 
CYP3A4 . Although no adjustment is recommended when ruxolitinib is co- administrated with 
CYP3A4 inducer, potential drug-drug interactions  might  occur. This study will be the first time 
ruxolitinib and enasidenib will be used in combination for this patient population. Therefore, the 
safety of the combination will be confirmed in the first six patients who accrue. If no more than one 
patient out of the initial six has a treatment -related Grade 3 or higher adverse event attributable to the 
study drugs, the combination therapy will be considered safe.  If more than one patient out of the 
initial six has limiting toxicity, the trial will be suspended, and the safety data will be further reviewed.  
If drug- related G rade 3 clinically relevant non -hematologic toxicity is attributable to one or both of 
the drugs (based on known adverse events profile), dose interruption of that particular drug(s) is 
mandatory. Patients who experience Grade 3 drug related clinically relevant non-hematological 
toxicity may be given a subsequent course one dose level below the previous course, but the patient 
must have recovered to G rade ≤1 before initiation of the next course. If attributable to ruxolitinib, 
dosing modifications in Table s 2a and 2b should be utilized. If attributable to enasidenib , dosing 
modification in Table 3b should be utilized. If a patient has drug -related clinically relevant G rade 4 
non-hematologic toxicity, he/she will be taken off study. The dose of therapeutic agents can be 
decreased, at the discretion of treating physician, for chronic G rade 2 non- hematologic toxicity. 
Additionally, ruxolitinib dosage may be adjusted if pat ients develop decline in Creatinine clearance 
(CrCl) as calculated by the Cockcroft - Gault equation as follows: Reduce ruxolitinib dose by one dose 
level for patients with moderate (CrCl 30 -59 mL/min) or severe renal impairment (CrCl 15-29 
mL/min) if the p atient is receiving a ruxolitinib dose of 10 mg BID or higher. (Per FDA package 
insert for ruxolitinib).  
Myelosuppression and cytopenias are expected outcomes of MF disease processes and MF treatments 
and per se will not constitute adverse events except a s follows: hematologic toxicity will be 
considered Grade 4 neutropenia with fever that does not clinically resolve within 14 days in the setting of optimal interventions or Grade 4 thrombocytopenia with clinically -significant bleeding. Dose 
interruption of  the drug to which the adverse event is attributable is required. Patients may be given 
a subsequent course one dose level below the previous course, but the patient must have recovered to grade ≤ baseline at study entry. The dose of therapeutic agents can  be decreased, at the discretion of 
treating physician, for chronic G rade 3 hematologic toxicity.  
10.1.1  QT PROLONGATION  
QTc interval has been observed in dogs at relatively low doses of enasidenib . Prolonged QTc interval 
has not been seen in other animal species at high doses.  Subjects who experience prolongation of 
the heart -rate corrected QT interval, Frideric ia’s correction (QTcF) to  > 480 msec (Grade ≥ 2) while 
treated with  enasidenib , should be promptly evaluated for causality of the QTc prolongation and 
managed according to the following guidelines: 
• Levels of electrolytes (potassium, calcium, and magnesium) should be checked and supplementation given to correct any values outside the normal range. 
• Concomitant medications should be reviewed and adjusted as a ppropriate for medication 
with known QT prolonging effects. 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 26 of 77   10 Nov 2021  
Confidential  
• If no other cause is identified and the I nvestigator believes it is appropriate, particularly if 
QTc remains elevated (after above measures have been implemented, or as determined by 
the I nvestigator), investigational product may be interrupted, and an ECG should be 
rechecked in approximately 1 week after the QTc prolongation was first observed, or more 
frequently as clinically indicated.  
o If QTc has recovered or improved and the I nvestigato r believes it is safe to do so, 
re-challenge with enasidenib should be considered if held. ECGs should be conducted 
at least weekly (e.g. , at every scheduled visit) for 2 weeks following QTc 
reduction ≤ 480 msec. 
o If Grade 2 (QTcF> 480 and ≤ 500 msec), the dose of enasidenib may be reduced to a 
dose approved by the Study Chair without interruption of dosing. The e nasidenib  dose 
may be re -escalated to the prior dose in ≥ 14 days after QT prolongation has decreased 
to ≤ Grade 1.  
o If Grade 3 (QTcF> 500 msec), wh en QTc prolongation is first observed, hospitalization 
for continuous cardiac monitoring and evaluation by a cardiologist should both be 
considered. Dosing with enasidenib  will be interrupted. If QTc returns to within 30 ms 
of baseline or < 450 msec within 14 days, treatment may be resumed at a reduced dose. 
The enasidenib dose cannot be re -escalated following dose reduction for Grade 3 QTcF 
prolongation unless the prolongation was associated with an electrolyte abnormality or 
concomitant medication.  
o If Gra de 4 (QTcF> 500 msec or > 60 msec change from baseline with torsade de pointes 
or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia), subjects should be admitted to hospital when QTc prolongation is first observed for 
continuous cardiac monitoring and be discharged only after review by a cardiologist. 
Dosing with enasidenib should be permanently discontinued.
 
10.1.2   ABNORMAL LEVEL OF LI VER ENZYMES 
(HYPERBILIRUBINEMIA)  
Subjects with elevations in ALT ≥ 3 -fold ULN, subjects will be monitored using the algorithm:  
• Repeat LFT (i .e., ALT, AST, total bilirubin, ALP, GGT) within < 3 days of the initial test. 
Follow-up 2- 3 times weekly, and weekly when stable. 
• Perform additional diagnostic follow up: 
o Focused medical history, including revie w of prior history of liver or biliary disorders, 
concurrent symptoms, review of all concomitant medications 
(e.g., acetaminophen- containing medications, over -the-counter or herbal medications, 
nutritional supplements ) including any changes in medications, detailed review of 
alcohol use. 
o Hepatitis serology (anti -HAV, HBsAg, anti -HBs, anti -HB core, anti -HCV, HCV RNA, 
EBV and CMV screen), and autoantibodies ( e.g., ANA, anti -smooth muscle antibody) . 
o Complete physical examination. 
o Liver ultrasound and follow-up imaging as appropriate. 
o Additional evaluation as appropriate (INR, PT). 
Hyperbilirubinemia generally decreased in frequency as enasidenib treatment continued. \ 
 
 
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 27 of 77   10 Nov 2021  
Confidential  
 Table 1. Ruxolitinib initial dose for patients’ baseline platelet count by cohort*  
Cohort  Plt>100 X109/L Plt 50- 100 X109/L Plt 20- 50 X109/L Plt<20 X109/L 
Blast/Accelerated 
Phase  20 BID  15 BID  10 BID  5 BID  
Chronic Phase  15 BID  10 BID**  NA NA 
*Patients already receiving Ruxolitinib will begin trial at the dose they were on prior to combination therapy.  
**Chronic phase patients with platelet<75 will not be enrolled to the trial.  
Table 2a. Ruxolitinib  Dose Adjustment  for patients with accelerated and blast phase MF  for NON-
HEMATOLOGICAL AEs* 
Dose level  PATIENTS’ BASELINE PLATELET COUNT S 
Plt>100 X109/L Plt 50 -100 X109/L Plt 20 -50 X109/L Plt<20 X109/L 
+1 25 BID  20 BID  NA NA 
0 20 BID  15 BID  10 BID  5 BID  
-1 15 BID  10 BID  5 BID  5QD  
-2 10 BID  5 BID  5 QD Stop treatment  
-3 5 BID  5 QD Stop treatment   
-4 5 QD Stop treatment    
-5 Stop treatment     
* For patients with accelerated and blast phase MF, treatment will continue at the same dose regardless of platelet 
count.  
Table 2b. Ruxolitinib  Dose Adjustment  for patients with chronic phase MF  for thrombocytopenia or non -
hematological AEs  
Dose level  DOSE ADJUSTMENT FOR THROMBOCYTOPENIA  
 Plt>100 X109/L Plt 50- 100 X109/L Plt 20- 50 X109/L DOSE ADJUSTMENT FOR NON -
HEMATOLOGICAL AEs  +1 20 BID  15 BID  N/A 
0 15 BID  10 BID  5 BID*  
-1 10 BID  5 BID  5 QD 
-2 5 BID  5 QD Stop treatment  
-3 5 QD Stop treatment   
-4 Stop treatment    
 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 28 of 77   10 Nov 2021  
Confidential  
Table 3a. Enasidenib  Dose Adjustment  for thrombocytopenia  
MF chronic phase  
Cycle 1  MF chronic phase  
Cycle 2 and above  MF chronic phase  
Cycle 2 and above  MF chronic phase  
Cycle 2 and above  MF accelerated 
phase and blast 
phase  
Platelet >75X109/L Platelet >  50X109/L Platelet 35 -50X109/L Platelet<35X109/L Any platelet count  
50mg  100mg  50mg  Hold  100mg  
Table 3b. Enasidenib Dose  Adjustment for non- hematological AE  
Dose Level  Enasidenib  
  -1 50 mg QD  
   0 100 mg QD  
10.2  DOSE MODIFICATIONS FOR HEMATOLOGICAL AE ’S 
For subjects receiving ruxolitinib and enasidenib , ruxolitinib dosages will be adjusted as detailed in  
Table  2a and Table  2b. 
For chronic phase MF, i f platelets are reduced to <  20X109/L ruxolitinib should be stopped 
Ruxolitinib can be rechallenge d at 5mg BID when platelet s recover to > 20X109/L, and enasidenib 
could be added the subsequent cycle as long as platelets  recover to >50X109/L. 
Interrupt treatment for absolute neutrophil  count (ANC) less than 0.5 X 109 /L. After recovery of 
ANC above 0.75 X 109 /L, dosing may be restarted; restart dosing at 5 mg  per day lower than the dose  
prior to the treatment interruption. 
For patients with accelerated and blast phase MF, treatment will continue at the same dose regardless 
of platelet count or ANC. 
10.3  DOSE ESCALATIONS  
Patients may be escalated to the next higher dose level of ruxolitinib as per dose levels in Tabl e 2a 
in the event that a patient’s platelet count increases, after C ycle 3 of combined therapy  or in case of 
suboptimal response in the opinion if the investigator . Patients with chronic phase MF will escalate 
the dose of enasidenib  from 50mg to 100 mg in cycle 2 and ongoing if  platelet  count stays above  
50,000 at the end of cycle 1 (Table 3a ) and no other therapy emergent SAE of grade > 2 developed 
(except grade 2 hyperbilirubinemia that is permitted).  
Dose of ruxolitinib and enasidenib  cannot be simultaneously increased in the same cycle. Dose 
escalation is permitted if ALL  of the following criteria are met:  
1. No dose red uctions due to toxicity w ere requir ed in the prior cyc le 
2. No dose interruptions due to toxicity w ere requir ed in the pri or cycle 
3. The prior cycle w as not del ayed due to toxici ty 
4. The current cycle is not del ayed due to toxicity 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 29 of 77   10 Nov 2021  
Confidential  
5. ANC ≥ 1.0 x 109/L 
6. The patient has sub-optim al benefit, defined as a fa ilure to reduce p alpable spleen length by at 
least 50% and/or suboptim al improvement in di sease - related symptoms as assessed  by the 
Investigator. 
7. No development o f new on set transfusion dep endency  judged  to be due to ther apy 
10.4  CONCOMITANT MEDICATI ONS/TREATMENTS  
All supportive measures consistent with optimal subject care will be given throughout the study.  
Concomitant medications will be captured in the Case Report Form (CRF ) beginning at S creening. 
Packed red blood cell or platelet transfusions are allowed when necessary.  Growth factor use 
(including erythropoietin) is not allowed with the exception of the use of filgrastim (G -CSF) or 
pegfilgrastim, which is permitted ONLY when used to tre at febrile neutropenia or in patients who 
have prolonged (one week or more) G rade 3 -4 neutropenia, after approval from the Study Chair.  
Concurrent use of strong inducers of CYP3A4 (Rifampin, St. John’s Wort, carbamazepine, 
phenytoin) and/or the following strong inhibitors of CYP3A4 (protease inhibitor containing HIV anti -
retrovirals, cobicistat, clarithromycin, itraconazole, ketoconazole, nefadozone, and telithromycin) are 
prohibited.  Also prohibited are CYP2C9 substrate medications that have a narrow therapeutic range: 
phenytoin and warfarin.  
The following medications that are known to prolong QT interval are prohibited: amiodarone, arsenic 
trioxide, astemizole, azithromycin, bepridil, chloroquine, chlorpromazine, cisapride, citalopram, 
clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, escitalopram, flecainide, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, 
moxifloxacin, pentamidine, pimozide, probucol, procainamide, quinidine, sevoflurane, sota lol, 
sparfloxacin, terfenadine, thioridazine, or vandetanib. 
Concomitant use of other cytotoxic chemotherapeutic agents (e.g. anagrelide) or other experimental 
drug or therapy while the subject is on study is prohibited, except for  hydroxyurea.  
Patients w ill be pe rmitted to r eceive hydroxyurea while on study for a total of 3 cycles of combined 
therapy to contr ol leukocy tosis and thro mbocyt osis at the disc retion of t he treating physician. 
Patients who en ter study on hydr oxyurea will be pe rmitted to r emain on hydroxyurea for a t otal of 3 
cycles of combined therapy. Patients who continue to requir e hydr oxyurea af ter 3 cycles will be 
removed from study . 
Steroids are allowed for the treatment of IDH -Inhibitor Differentiation Syndrome (IDH -DS), if 
warranted, as standard of care. The use of chronic low -dose steroids to treat an underlying medical 
condition that is not a malignancy is permitted during the course of study treatment 
For patient’s requiring ant -fungal prophylaxis, intravenous micafungin is the preferred agent.  If 
micafungin is not feasible, the oral antifungal of choice would be posaconazole barring other patient 
specific factors that would preclude use of posaconazole.  
Given the solubility profile of  enasidenib , the exposure can be muc h lower for subjects with elevated 
gastric pH.  Thus antacids, H2 blockers, or proton pump inhibitors should be used only if medically 
necessary and with at least 4 hours of elapsed time after enasidenib administration.   
As enasidenib is an inhibitor of UGT1A1, the metabolism of drugs that are substrates for UGT1A1, 
including ezetimibe, raloxifene and raltegravir, may be slowed, leading to increased exposure to these 
compounds.  Therefore, subjects on these drugs should be switched to lower doses or altern ate 
therapies, if possible, or otherwise monitored for AEs associated with the respective products and 
elevations in bilirubin levels.  
10.5  IDH -INHIBITOR DIFFER ENTIATION SYNDROME ( IDH -DS)  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 30 of 77   10 Nov 2021  
Confidential  
Subjects treated with enasidenib may develop signs and symptoms of a  IDH-Inhibitor Differentiation 
Syndrome (IDH -DS).  This may include any of the following: unexplained fever, skin rash, 
leukocytosis, thrombocytosis, hypoxia, respiratory distress, interstitial pulmonary infiltrates, pleural 
and/or pericardial effusion, pe ripheral edema,  weight gain, or clinical deterioration.  No single sign 
or symptom may be considered per se as diagnostic of the syndrome.  It is recommended that the prophylactic and therapeutic measures indicated below be undertaken at the earliest manif estations of 
suspected IDH-Inhibitor Differentiation Syndrome (IDH- DS):  
• Enasidenib  may be held at the I nvestigator’s discretion , and must be held if severe symptoms 
persist after  48 hours of systemic steroid administration . 
• Prompt initiation of hydroxyurea at a suggested dose of 2 to 3 g PO two or three times daily . 
• Prompt administration of corticosteroids at a suggested dose of 10 mg of dexamethasone intravenously (IV) every 12 hours until the disappearance of symptoms and signs, and for a minimum of 3 days. 
• Initiation of furosemide per local standard practice, if clinically required . 
• Prompt initiation of leuka pheresis, if clinically required . 
Once the signs and symptoms resolve and the subject’s clinical condition improves, enasidenib may 
be reinitiated.  The dose of enasidenib at re -initiation is to be discussed with the Study Chair. 
For more information See Appendix D.  
10.6  NON -INFECTIOUS LEUKO CYTOSIS  
Initiation of treatment with the differentiating agents may lead to rapid WBC expansion not associated 
with infectious process and not manifesting with the signs and symptoms of IDH -Inhibitor 
Differentiation Syndrome (IDH- DS) discussed above.  
In subjects with elevated WBC, prompt initiation of hydroxyurea is suggested, as per standard local practices ( e.g., dose of 2 to 3 g PO twice or three times daily for WBC > 30 x 109/L). In case of severe 
leukocytosis (WBC >100 x 109/L), use of leukapheresis may be appropriate. Subject should be regularly monitored for changes in WBC count and for new signs and symptoms  of infection or IDH -
Inhibitor Differentiation Syndrome (IDH- DS). 
10.7  DISCONTINUATION OF RUXOLITINIB  AND ENASIDENIB  
Upon planned discontinuation of ruxolitin ib it is recommended to taper off the drug over the course 
of 4- 7 days and permissible to use prednisone daily during this period to blunt rebound of symptoms.  
Since patients will be on varying dosing regimens of ruxolitinib, investigators are urged to disc uss 
the ruxolitinib  taper plan with Study Chairs.  
If a patient has to have ruxolitinib held abruptly for the occurrence of adverse events (e.g. major bleeding, sig nificant thrombocytopenia, etc. ), then the ruxolitinib may be stopped WITHOUT a taper 
and a pulse of prednisone  may be  utilized if deemed necessary by the I nvestigator.  
Enasidenib  may be interrupted or stopped without tapering. 
10.8  EVALUATION DURING TR EATMENT/INTERVENTION  
Baseline evaluations are to be conducted within 28 days of the first study drug administration, unless 
otherwise indicated within the Schedule of Assessments outlined in Table 4. All scheduled visits will 
have a ± 7 days window unless otherwise stated or indicated within the Schedule of Assessments.  
11. WHEN AND HOW TO WITHDRAW SUBJECTS  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 31 of 77   10 Nov 2021  
Confidential  
In accordance with the Declaration of Helsinki and the guidelines of the country of the participating 
MPN -RC Clinical Study Center, each subject is free to withdraw from the study at any time.  An 
Investigator also has the right to withdraw a subj ect from the study in the event of the patient suffering 
an intercurrent illness, adverse events, or other reason s concerning the health or well -being of the 
patient, or in the case of lack of cooperation by the patient. All serious adverse reactions need to be 
followed up until resolution and information returned to study coordinators. 
Should a subject decide to withdraw after administration of study drug, or should the I nvestigator 
decide to withdraw the subject, all efforts should be made to complete and  report the observations up 
to the time of withdrawal as thoroughly as possible. A final evaluation, the reason for, and the date of 
withdrawal must be recorded on the CRF. The last visit for each subject will be defined as a study 
discontinuation/ end-of- study visit, which will occur 30 (±7 days) days after time of treatment 
withdrawal.  
Subjects with clinically significant abnormal laboratory values as determined by the Investigator or 
who have ongoing clinically significant treatment- related adverse even ts during their last scheduled 
clinical evaluation will be monitored and treated until resolution or stabilization is achieved; or, in the event that the subject’s condition is not likely to improve because of disease progression, until the 
cause of the ab normal test result or adverse event can be determined.  
11.1  DATA  COLLECTION AND FOLLO W-UP FOR WITHDRAWN 
SUBJECTS  
The reason for and date of withdrawal from study drug treatment; and the reason for and date of withdrawal from the study will be recorded on the case report form (CRF). If a subject 
withdraws consent, every attempt will be made to determine the reason. If the reason for withdrawal is an adverse event or a clinically significant abnormal laboratory test result, 
monitoring will continue until the  event has resolved or stabilized, until the subject is referred 
to the care of a local health care professional, or until a determination of a cause unrelated to 
the study drug or study procedure is made. The specific event or test result(s) must be recor ded 
on the CRF. All evaluations will be performed, according to the protocol, 30 days ( ±7 days) 
after the patient is withdrawn from treatment.  
Patients will continue to be followed for long term survival every 3 months by telephone 
encounter or medical record review to determine the following variables: alive versus deceased 
and type of current therapy. Patients will be followed for this long term survival data until death, confirmed lost to follow up, or a maximum of 1 year after end of treatment.  
A subject will be considered to be lost to follow -up if all of the following criteria have been 
met: 
1. More than three phone calls to the subject are unanswered.  
2. A next of kin is contacted and no information is available. 
3. The referring physician is contacte d and no information is available.  
4. A telegram or certified letter is unanswered.  
11.2  DURATION OF FOLLOW -UP 
The patient will have an end of study visit at 30 days after discontinuation of the protocol 
treatment , with a window of ±7  days, to assess for AEs . 
Patients will continue to be followe d for long term survival every 3  months by telephone 
encounter or medical record review to determine the following variables: alive versus deceased 
and type of current therapy. Patients will be followed for this long term survival data until death, confirmed lost to follow up, or a maximum of 1 year after end of treatment.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 32 of 77   10 Nov 2021  
Confidential  
11.3  REMOVAL OF PATIENTS FROM PROTOCOL THERAP Y 
Patients will be removed from therapy when any of the criteria listed in When and How to 
Withdraw Subjects section  apply. Notify the Principal Investigator and  document the reason 
for study removal and the date the patient was removed in the Case Report Form.  
11.4  PATIENT  ACCRUAL  
Subjects are considered evaluable as long as they have si gned informed consent, are eligible 
for participation and started study treatment. The maximum sample size in the Phase II 
(accelerated/blast- phase) is 20 evaluable patients.  Allowing for enrollment of up to 2 additional 
patients to account for ineligibility, cancellation, major treatment violation, or other reasons , 
this study will enroll a maximum of 22 patients in the Phase II AP/BP cohort.  The maximum 
sample size in the chronic phase MPN is 9 evaluable patients.  Allowing for enrollment of up 
to 1 additional patient , this study will enroll a maximum of 10 patients in the descriptive chronic 
phase MPN cohort.  Therefore, a maximum total of 32 (22 +10) patients will be enrolled in the trial. 
12.0  STUDY TIMELINES  
 
Baseline evaluations are to be conducted within 30 days of the first study drug administration, unless 
otherwise indicated within the Schedule of Assessments outlined in Table 4.  All scheduled visits will 
have a ± 7 days window unless otherwise stated or indicated within the Schedule of Assessments 
outlined below. 
Ruxolitinib and enasidenib will be given orally in 28 - day cycles. Attempts will be made to provide an 
adequate treatment period with the combination of at least 6 cycles, unless significant toxicity is 
observed, to account for delayed time to response observed with biologic agents. Interval Milestone 
Response Assessment  (IMRA) can be performed at the beginning of any cycle after cycle 1 if specific 
milestones are achieved that will prompt such an  evaluation. Specific milestones that will prompt 
assessment consist of clearance of blasts from peripheral blood in accelerated/blast phase patients, which will prompt bone marrow aspirate and biopsy. In addition progression of disease (as determined 
by an increase in blasts in the peripheral blood - defined as doubling of blasts % and achieving more 
than 10% in the chronic phase patients  at least 7 days apart ) will prompt IMRA.  Responders will 
continue therapy indefinitely unless progression of disease occurs, toxicity warranting discontinuation 
of therapy is observed, or at the discretion of the treating physician. Patients will have an end of study visit for a safety follow -up at 30 days after their last dose of therapy.  
13.0  STUDY END POINT S 
13.1  PRIMARY ENDPOINT  
• The proportion of treated accelerated- phase and blast -phase MPN patients (primary cohort) 
that achieve a best response of either complete response (CR) , Partial Response (PR), or 
complete response with incomplete recovery of counts (CRi), when treated with the combination of ruxolitinib with enasidenib within 6 cycles  of combined therapy. 
13.2  SECONDARY ENDPOINTS  
• To assess the efficacy of the combination of ruxolitinib with enasidenib in patients with 
accelerated -phase and blast -phase disease using complete (CBR) and partial bl ast response 
(PBR).  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 33 of 77   10 Nov 2021  
Confidential  
• The proportion of treated patients with MF -CP and 4% -9% circulating blasts  that achieve 
complete response (CR) Partial Response (PR), clinical improvement (CI) with the 
combination of ruxoliti nib and enasidenib  within 6 cycles of combined therapy.   
• To assess the impact of the combination of ruxolitinib with enasidenib on the overall 
survival of advanced phase MPN patients  
13.3  SAFETY ENDPOINTS  
• The proportion of patients developing  treatment -emergent  hematological and non-
hematological adverse events for the combination of ruxolitinib and enasidenib . 
13.4  EXPLORATORY ENDPOINT S 
• The proportion of patients who achieve improvement quality of life as assessed by the by the Myelofibrosis Symptom Assessment Form ( MF-SAFv4.0 ) with the combination of 
ruxolitinib and enasidenib   
• Assess the pharmacodynamics of ruxolitinib and e nasidenib  when combined in this 
population. 
• Assess the effects of combined therapy on gene expression and global methylation status.  
• Assess changes in mutant allele burden and clonal architecture of disease.  
14.0  STUDY PROCEDURES  
Study Design  
This is a multicenter, Phase II trial designed to assess the effect of ruxolitinib and enasidenib 
combination in subjects with accelerated or blast- phase MPN and subjects with chronic phase Primary 
Myelofibrosis, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF, post -
PV MF, or post -ET MF) with 4 -9% blasts. Patients will receive ruxolitinib and e nasidenib  orally on 
days 1 -28 of a 28- day cycle.  
Specifically , a Phase II Simon  min-max design will be conducted in accelerated or blast -phase MPN 
patients (20 patients) and a descriptive cohort of up to 9 chronic phase patients.   
Intervention 
Patients who meet eligibility criteria will be treated with ruxolitinib and e nasidenib  orally on day s 1-28 
of a 28- day cycle. Cycles will be continued until the patient wishes to be removed from the study, 
unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs. 
14.1  SCREENING/BASELINE P ROCEDURES  
Assessments performed exclusively to determine eligibility for this study will be done only after obtaining informed consent. Assessments performed for clinical indications (not exclusively to 
determine study eligibility) may be used for baseline values even if the studies were done before 
informed consent was obtained. 
All screening procedures must be performed within 30 days prior to registration u nless otherwise 
stated. The screening procedures include: 
• Patient Informed Consent  
Before a patient undergoes screening, a medically qualified member of the Study Team who has 
been specifically trained in the implementation of this Protocol during the Site Initiation Visit or thereafter, such as the Site Principal Investigator, any of the co -Investigators, or a Clinical 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 34 of 77   10 Nov 2021  
Confidential  
Research Nurse must obtain documented consent from each potential patient prior to participating 
in a clinical trial.  
Consent must be documented by the patient’s dated signature or by the patient’s legally 
acceptable representative’s dated signature on a consent form along with the dated signature of 
the person conducting the consent discussion. A copy of the signed and dated consent form should 
be given to the patient before participation in the trial.  
The initial informed  consent form, any subsequent revised written informed consent form and 
any written information provided to the patient must receive the IRB/EC’s approval/favorable opinion in advance of use. The patient or his/her legal representative should be informed i n a 
timely manner if new information becomes available that may be relevant to the patient’s willingness to continue participation in the trial. The communication of this information will be 
provided and documented via a revised consent form that captures the patient’s or legal 
representative’s dated signature. The informed consent will adhere to IRB/EC requirements, 
applicable laws and regulations and Sponsor requirements.  
• Demographics (age, gender, race, ethnicity)  
• Medical History  (A medical history will be obtained by the Investigator or qualified designee. 
Medical history will include all active conditions, and any condition diagnosed within the prior 
10 years that are considered to be clinically significant by the Investigator. Details regarding the 
disease for which the patient has enrolled in this study will be recorded separately and not listed 
as medical history ). 
• Prior Treatment Details  (The Investigator , or qualified designee , will review all prior cancer 
treatments including system ic treatments, RT and surgeries ) 
• Bone marrow biopsy and aspirate with cytogenetics and molecular genetic profiling for presence of JAK2 (or MPL or CALR mutation status in the case that no JAK2 mutation is detected) as well as IDH2 mutation status. Bone marrow biopsy obtained within 84 days prior to screening in the 
absence of disease modifying therapy may be used for determining eligibility. Mutational 
profiling may be carried out at local laboratories and does not require central laboratory confirmation. 
• Physical exam in cluding vital signs, body weight and height, and spleen and liver measurements 
• Transfusion history for 3 months prior to D ay 1 
• Review previous concomitant medications  within 90 days of screening and all myeloproliferative 
neoplasms directed therapies since time of diagnosis 
• Complete B lood Count (CBC) with  differentials  (includes platelet count)  
• Chemistries (LDH, total and direct bilirubin, phosphorus, albumin, uric acid, Na, K, Cl, Mg, CO2, BUN, Cr, glucose (random), Ca, AST, ALT, Alk Phos, total protein)  
• Lipid Panel 
• Urinalysis  
• Pregnancy test, urine or blood, with a sensitivity of at least 50 mIU/mL (for FCBP only) 
• Eastern Cooperative Oncology Group (ECOG) performance status 
• ECG  
• Spleen volume assessment by CT scan or MRI  
• Cardiac function assessment ( LVEF  ) by ECHO or MUGA  
• Review patient eligibility criteria  
14.2  REGISTRATION PROCEDURES  
Only MPN -RC approved centers may participate and register patients to this study.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 35 of 77   10 Nov 2021  
Confidential  
To register a potential participant, complete the Registration Form  for the trial located  at the study 
REDCap link provided by the Mayo Statistical Data Center.  This form confirms eligibility criteria 
and informed consent and contains basic demographic and clinical information.  Once eligibility is confirmed and informed consent has been obtained, registration of a patient in the trial can occur.  
After completion of this form, a unique patient ID will be assigned by the system.  An email 
notification will be sent to the MPN -RC Administrative and Statistical and Data Center core for each 
regis tered patient.   
14.2.1   SITE REGISTRATION WI TH MPN -RC  
Before an MPN -RC institution can enroll patients, protocol specific regulatory documents must 
be submitted to the MPN -RC Central Coordinating Office via E -mail (PDF file preferred) or 
fax: 
MPN -RC Central Coordinating Office  
Phone: (212) 241-9138 
Fax: (212) 876-5276 
MPNRC_ClinicalTrialCentralOffice@mssm.edu  
  
Required Protocol Specific Regulatory Documents (E -mailed by PDF format prefe rred):  
1. Submit a copy of IRB approval for MPN- RC 119  
2. Submit a copy of the IRB approved consent form for MPN-RC 119 
3. Submit a copy of the CV of the investigational pharmacist and Pharmacy license  
4. Submit a copy of the site’s drug destruction policy 
5. Submit a copy of a signed and dated CV and medical license of the Principal Investigator  
6. Submit a copy of Form FDA 1572 as completed by the Principal Investigator 
  
Before an MPN -RC institution can enroll patients , please contact the Clinical Central Office  
(e-mail: MPNRC_ClinicalTrialCentralOffice@mssm.edu ), to ensure that a  slot is available for 
enrollment prior to approaching a patient about possible participation in this trial. 
This study uses the MPN -RC on -line Patient Registration system 
(https://redcap2.mayo.edu/redcap/).
 Registration will be accepted only through use of the MPN -
RC database. Registration must occur prior to the initiation of therapy.  
Confirm eligibility criteria and comp lete the on -line Registration Worksheet.  
If the registering clinical research coordinator (CRC) requires assistance, he/she may 
consult the on -line help file located under the Help menu of the MPN -RC application or 
call the central office.  
When the patient is registered to MPN -RC 119, a patient identification number will be 
generated.  Registration will not be completed if eligibility requirements are not met for the 
selected trial.  
The registering institution will receive a Confirmation of Registration em ail from the 
database that should be printed and included in the patient chart. If a registering institution needs to correct the registration form, contact the MPN-RC Statistics and Data Center at 
Mayo (DLARZmpnrcstats@mayo.edu) and the Clinical Central O ffice: E-mail:
 
MPNRC_ClinicalTrialCentralOffice@mssm.edu . 
Before Study Drug Shipment  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 36 of 77   10 Nov 2021  
Confidential  
Before Study Drug can be shipped to the MPN -RC center to begin accruing patients, the above 
regulatory documents are required to be emailed to  the MPN -RC Central Office to the attention 
of the Clinical Trials Manager, as noted above.  
14.3  INFORMED CONSENT  
The patient must be aware of the neoplastic nature of his/her disease, as well as of the expected life 
expectancy at his/her stage of disease.  The patient must willingly consent after being informed of the 
procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side 
effects, risks, and discomforts. BRANY Institutional R eview Board (or other local ethics committees 
for non- US sites)  approval of this protocol and of its consent form is required. 
14.4  DATA MANAGEMENT  
After registration of a patient, additional case report forms in the study database will be available for 
completion according to the Schedule of Events (Table 4).  All clinical data and obtained specimens 
will be labeled with the patient ID assigned at registration for the entire duration of the subject’s 
participation.   
Data for all clinical variables will be stored in the REDCap database.  Access to the REDCap database 
will be limited to MPN -RC investigators  and designees;  users at each site will only be able to view 
the records pertaining to subjects enrolled at their particular site.  
15. TREATMENT PERIOD  
The subject must be enrolled into the study, at the latest 30 days from signing the ICF, following 
Sponsor review of eligibility. The Treatment Period begins at Cycle 1 D ay 1 and ends at the 
End-of-Treatment Visit. During the Treatment Period, all s ubjects will be closely monitored for 
safety. Toxicities (AEs and laboratory abnormalities) will be evaluated and graded according to the CTCAE.  During this period the following assessments should occur:   
• Bone marrow biopsy and aspirate with cytogenetics  and molecular genetic profiling for presence 
of JAK2 (or MPL or CALR mutation status in the case that no JAK2 mutation is detected) as well 
as IDH2 mutation status.
 This is done at C4 D1 ( for all accelerated patients, may be done at  the 
discretion of the Investigator for chronic phase patients), C 7 D1 (for all patients) , C10 D1( for 
accelerated phase patients, may be done at the discretion of the Investigator for chronic phase 
patients), and every 6 cycles, thereafter  (for all patient s). 
• Transfusion history will be collected on Day of each cycle  
• Pregnancy Test  
• A physical exam including a review of current medical conditions and medications  
• Vital signs (heart rate, breathing rate, blood pressure, temperature, weight, and height) 
• ECOG performance status  
• Adverse events and concomitant medications  
• Complete blood counts and serum chemistry 
• Spleen volume assessment by CT/MRI  at C7 D1 , and C10 D1 
• ECG , day 1 of each cycle until Cycle 7  
• Research blood sample collection  
• MF-SAFv4.0 questionnaire (paper or electronic)  
• Enasidenib  administration  
• Medication diary collected and  new one dispensed  
 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 37 of 77   10 Nov 2021  
Confidential  
15.1  END OF TREATMENT VIS IT 
The post -treatment period includes the time after the End of Treatment Visit until the End of Study 
Visit. This period is 30 days.  The following assessments should occur: 
• Bone marrow biopsy and aspirate with cytogenetics and molecular genetic profiling fo r presence 
of JAK2 (or MPL or CALR mutation status in the case that no JAK2 mutation is detected) as well 
as IDH2 mutation status. Mutational profiling may be carried out at local laboratories and does 
not require central laboratory confirmation.  
• Physical exam   
• Vital signs, body weight and height, and spleen and liver measurements 
• Concomitant medications and adverse events  
• CBC and differentials  
• Serum chemistry  
• ECG  
• Spleen volume assessment by CT scan or MRI  
• Research blood sample collection  
• MF-SAFv4.0 questionnaire (paper or electronic)  
15.2  END OF STUDY VISIT  
The visit is the mandatory safety follow -up visit and should be conducted approximately 30 days after 
the end of trial treatment or before the initiation of a new anti -cancer treatment, whichever comes 
first. All AEs that occur prior to the End of Study Visit should be recorded.  
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 38 of 77   10 Nov 2021  
Confidential  
Table 4. Schedule of Events  
Procedure Screeni ng 
Period  Cycl e1-2 Cycl e 3-6 Cycle 7 and 
beyond End of 
treatment  End of  
Study11 Survival 
Follow Up  Day 
15 Day 
8 Day 
15 Day 
22 Day 
1 Day 1  
Inform ed Cons ent X          
Medic al History 
(includi ng prior  
MF-direc ted therapies)  X          
Physical examination1 X X  X  X X X X  
Transfusi on His tory X2 X2    X X X X  
Pregnancy test (for  
FCBP  
only)3 X X X X X X X X X  
CBC and d ifferent ials X X X X X X X X X  
Serum  Chemistry4  X X X X X X X X X  
Urinalysis X          
12-Le adECG14 X X X X X X X X X  
Echo/MUGA  X          
Bone Marrow Aspirate 
and 
Biopsy6,7 X6     X6,7 X6,7  X6  
Biospecim en 
Collecti on– 
Peripheral blo od X12 X12    X12 X12  X12  
Adverse ev ent 
evaluation  X  X  X X X X  
Concomitant 
medications, 
therapies, and 
procedures evaluation X X  X  X X X X  
Spleen V olume 
Assessment8 X      X8  X  
Response A ssessment       X9, 13  X  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 39 of 77   10 Nov 2021  
Confidential  
 
1. Includes vital signs, weight, height and measurements of the spleen and liver.  Height is only required at screening. 
2. Subjects must have 3 months documented transfusion history prior to Day 1 . 
3. Pregnancy test, urine or blood, with a sensitivity of at least 50 mIU/mL, within 10 – 14 days prior to and again within 24 hours of 
starting  enasidenib ; then every week x 4, then monthly for all FCBP with regular menstrual cycles, or every 2 weeks if irregular cycles. 
4. Includes sod ium, potassium, chloride, carbon dioxide, blood urea nitrogen, creatinine, total bilirubin, alanine aminotransferase, , and 
glucose. Magne sium, , PT/PTT and INR need to only be done at screening . Lactate dehydrogenase u ric Acid, phosphorus need to be 
checked day 1 of every cycle and in the EOS  
5. If not done within 3 days of Day 1.  
6. Bone Marrow Aspirate and Biopsy to be collected at baseline (within 84 days from screening is also permissible with permissio n from 
the Study Chair), Cycle 4 day 1 (at the discretion of the Investigator  for chronic phase patients ), Cycle 7 day 1 , Cycle 10 day1 (at the 
discretion of the Investigator  for chronic phase patients ), every 6 cycles, thereafter, and at the end of study  visit. Peripheral blood draws 
may be us ed to perform JAK2 mutation testing if the bone marrow is not aspirable.  
7. May be omitted if so decided by the treating physician. Should be done to confirm complete response and when clinically indic ated.  
8. CT scan or MRI to be performed at baseline, C ycle 7, Cycle 10, and at the end of study.  
9. Response assessments (IWG -MRT criteria 2013 and ELN revised response criteria  ) should be after 6 cycles and every 3  - 6 cycles 
thereafter for the remainder of the study.  
10. Collect pill diaries and any unused study drug t o review for compliance prior to each cycle through cycle 24. After cycle 24, review 
patient drug diaries for ruxolitinib and e nasidenib  at each protocol visit. 
11. The discontinuation visit will be considered as such on the date the patient is taken off treatment. The patient will have an end of study 
visit approximately 30 days after the end of trial treatment  to assess for AEs.  
12. Peripheral blood biomarker samples will be collected at screening, and day 1 of Cycle 1 - Cycle 7, every 3 cycles  thereafter , and at  the 
end of study, in conjunction with standard -of-care blood draws. Bone marrow aspirate samples will be collected whenever a bone 
marrow examination is scheduled to take place as designated in item 6 above.   
13. Interval Milestone Response assessment can b e performed at the beginning of any cycle after C ycle 1 if specific milestones are achieved 
as specif ied in study timeline. 
14. ECGs done day 1 of each cycle until Cycle 7, ECGs should be done at EOS. \ 
15. Patients will continue to be followed  for long term survival every 3 months by telephone encounter or medical record review to 
determine the following variables: alive versus deceased and type of current therapy. Patients will be followed for this long  term 
survival data until death, confirmed lost to follow up, or a maximum of 1 year  after end of treatment. 
 
16. ADVERSE EVENT S 
Adverse event data collection and reporting, which are required as part of every clinical trial, are done 
to ensure the safety of subjects enrolled in the studies as well as those who will enroll in future studies 
using similar agents. Adverse events are r eported in a routine manner at scheduled times during a trial. 
Additionally, certain adverse events must be reported in an expedited manner to allow for optimal monitoring of patient safety and care.  
All patients experiencing an adverse event, regardless of its relationship to study drug, will be 
monitored until:  
• the adverse event resolves or the symptoms or signs that constitute the adverse event return to 
baseline;  
• any abnormal laboratory values have returned to baseline;  
• there is a satisfactory explanation other than the study drug for the changes observed; or Nail Clippings  X          
Study drug dispensing10  X    X X    
MF-SAFv4.0  Survey   X X X X X X X X  
Survival Data15          X 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 40 of 77   10 Nov 2021  
Confidential  
death.  
16.1  DEFINITIONS  OF ADVERSE EVENT  
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or 
worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values, regardless of etiology.  Any worsening (i.e., any clinically significant adver se 
change in the frequency or intensity of a pre- existing condition) should be considered an AE. A 
diagnosis or syndrome should be recorded rather than the individual signs or symptoms of the diagnosis or syndrome 
16.2  SEVERITY  OF ADVERSE EVENT  
All non-hematologic adverse events will be graded according to the NCI Common Terminology 
Criteria for Adverse Events version 5.0  (CTCAE) . The CTCAE is available at 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf 
If no CTCAE grading is available, the severity of an AE is graded as follows:  
• Mild ( Grade 1): the event causes discomfort without disruption of normal daily activities. 
• Moderate ( Grade 2): the event causes discomfort that affects normal daily activi ties. 
• Severe ( Grade 3): the event makes the patient unable to perform normal daily activities or 
significantly affects his/her clinical status.  
• Life-threatening (G rade 4): the patient was at risk of death at the time of the event.  
• Fatal ( Grade 5): the event caused death.  
16.2.1   SERIOUS  ADVERSE EVENTS (SAE)  
An adverse event is considered serious if it results in ANY of the following outcomes:  
• Results in death. If death results from (progression of) the disease, the disease should be 
reported as event (SAE) itself.  
• Is life -threatening. (The patient was at risk of death at the time of the event; it does not refer 
to an event that hypothetically might have caused death if it were more severe.)  
• Requires in -patient hospitalization or prolongation of existin g hospitalization 
for ≥ 24 hours. 
• Results in persistent or significant disability or incapacity.  
• Is a congenital anomaly/birth defect 
• Is an important medical event 
Events not considered SAEs are hospitalizations for: 
1. A standard procedure for protocol therapy administration. However, hospitalization or 
prolonged hospitalization for a complication of therapy administration will be reported as 
an SAE.  
2. Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.  
3. The administration of blood or platelet transfusion as routine treatment of studied 
Indication.  However, hospitalization or prolonged hospitalization for a complication of 
such transfusion remains a reportable SAE.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 41 of 77   10 Nov 2021  
Confidential  
4. A procedure for protocol/disease- related  investigations (e.g., surgery, scans, endoscopy, 
sampling for laboratory tests, bone marrow sampling).  However, hospitalization or 
prolonged hospitalization for a complication of such procedures remains a reportable SAE.  
5. Hospitalization or prolongation of hospitalization for technical, practical, or social reasons, in absence of an AE.  
6. A procedure that is planned (i.e., planned prior to starting of treatment on study); must be 
documented in the source document and the CRF.  Hospitalization or prolonged 
hospitalization for a complication remains a reportable SAE.  
7. An elective treatment of or an elective procedure for a pre- existing condition unrelated to 
the studied indication.  
8. Emergency outpatient treatment or observation that does not result in admission, unless fulfilling other seriousness criteria above. 
If an AE is considered serious, both the AE page/screen of the CRF and the MEDWATCH form must be completed.  For each SAE, the Investigator will provide information on severity, start 
and stop dates, relationship to IP, action taken regarding IP, and outcome. 
• Important Me dical Events (IME) tha t may not result i n deat h, be life threatening, or  requir e 
hospita lization m ay be consider ed serious when, ba sed u pon medi cal judgment, they m ay 
jeopardize the patient or subject and m ay require medi cal or su rgical interventi on to prevent 
one o f the o utcomes listed in this definition 
o Exampl es of such medical events include a llergic bronchospas m requiri ng intens ive 
treatment in an emergency  room or at home, blood dy scrasias or convulsions that do 
not result in i npati ent hospitaliz ation, or the development of drug depende ncy or  drug 
abuse (21C FR312.32). 
Important medical events as defined above may also be considered serious adverse events. Any 
imp
ortant medical event can and should be reported as an SAE if deemed appropriate by the 
investigator.  
The term “severe” is often used to describe the intensity o f a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache).  This criterion is not the same as “serious” which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject’s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.  
16.2.2   ADVERSE EVENTS OF SPECIAL INTERE ST (AESI)  
An adverse event of special interest (AESI) is one of scientific and medical interest specific to 
understanding of the Investigational Product and may require close monitoring of patients and rapid 
communication by the Investigator to the S ponsor. An AESI may be serious or non -serious. The rapid 
reporting of AESIs allows ongoing surveillance of these events in order to characterize and understand 
them in association with the use of this investigational product. 
AESIs  for enasidenib  include but are not limited to events with AESIs observed with e nasidenib  include 
those specified in the IB.  
16.3  CAUSALITY  
The Investigator must determine the relationship between the administration of IP and the occurrence 
of an AE/SAE as unrelated, possible, probable or definite as defined below . 
• Definite – The AE is clearly related  to the study treatment.  
• Probable – The AE is likely related to the study treatment.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 42 of 77   10 Nov 2021  
Confidential  
• Possible – The AE may be related  to the study treatment.  
• Unrelated – The AE is clearly NOT related to the study treatment.  
When a determination of possibly, probable or definite is used, the Investigator should also determine 
whether the suspected agent is ruxolitinib or enasidenib.  
16.4  DURATION  
For both AEs and SAEs, the Investigator will provide a record of the start and s top dates of the event.  
16.5  ACTION TAKEN  
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable (e.g., 
discontinuation, interruption of IP, as appropriate) and report if concomitant and/or additional 
treatments were given for the event.  
16.6  OUTCOME  
The Investigator will report the outcome of the event for both AEs and SAEs.  All SAEs that have not resolved upon discontinuation of the subject’s participation in the study must be followed until recovered (returned t o baseline), recovered with sequelae, or death (due to the SAE). 
16.7  OVERDOSE  
Overdose, as defined for this protocol, refers to enasidenib and ruxolitinib dosing only (as applicable).   
On a per dose basis, an overdose is defined as the following amount over the protocol -specified dose of 
enasidenib and ruxolitinib assigned to a given patient, regardless of any associated adverse events or 
sequelae - PO any amount over the protocol -specif ied dose.  On a schedule or frequency basis, an 
overdose is defined as anything more frequent than the protocol required schedule or frequency.  .  
Complete data about drug administration, including any overdose, regardless of whether the overdose 
was acci dental or intentional, should be reported.    
To date, doses of enasidenib up to 650 mg QD were well tolerated in clinical trials. No information is 
currently available regarding overdose with  enasidenib . In the event of overdose with toxicity, 
supportive clinical care should be provided.  
16.8  ABNORMAL LABORATORY VALUES  
An abnormal laboratory value is considered to be an AE if the abnormality: 
• results  in discontinuation from the study;  
• requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or 
• is judged to be of significant clinical importance, e.g. , one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing condition. 
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion need to 
be documented as a serious adverse event.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE. If possible, the 
laboratory abnormality should be recorded as a medical term and not simply as an abnormal laboratory 
result (e.g., record thrombocytopenia rather than decreased platelet).  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 43 of 77   10 Nov 2021  
Confidential  
17. REPORTING REQUIREMENTS FOR ADVERSE EVENT S 
All adverse events must be recorded in the subject's medical records and on the Case Report 
Form  from the time the subject signs informed consent until 30 days after the last dose of IP and those 
SAEs made known to the investigator at any time thereafter that are suspected of being related to IP .  
The onset and end dates, severity, duration, effect on study drug administration (e.g. discontinuat ion), relationship to study drug, and administration of any other drug(s) to treat this 
event will be recorded for each adverse event. The BRANY Institutional Review Board is 
charged with the responsibility of reviewing and maintaining records of all Serious Adverse Events occurring in patients who are participating in BRANY IRB approved research trials at BRANY sites
. All SAEs must be reported to Celgene Drug Safety within 24 hours of the Investigator’s 
knowledge of the event by facsimile, or other appropriate method, using the SAE Report Form, or 
approved equivalent form. 
17. 1  STEPS TO DETERMINE I F AN ADVERSE EVENT REQUIRES 
EXPEDITED REPORTING  (WITHIN 24 HOURS)  
Step 1 : Identify the type of adverse event using the NCI Common Terminology Criteria for 
Adverse Events version 5.0 (CTCAE).  
Step 2 : Grade the adverse event using the NCI CTCAE v5.0. 
Step 3 : Determine whether the adverse event is related to the protocol therapy  
Attribution categories are as follows:  
• Definite – The AE is clearly related  to the study treatment.  
• Probable – The AE is likely related to the study treatment.  
• Possible – The AE may be related  to the study treatment.  
• Unrelated – The AE is clearly NOT related to the study treatment.  
Note : This includes all events that occur within 30 days of the last dose of protocol 
treatment. Any event that occurs more than 30 days after the last dose of treatment and is 
attributed (possibly, probably, or definitely) to the agent(s) must also be reported 
accordingly.  
Step 4 : Determine the prior experience of the adverse event.  
Expected events are those that have been previously identified as resul ting from administration 
of the agent. An adverse event is considered unexpected, for expedited reporting purposes only, 
when either the type of event or the severity of the event is not  listed in:  
• the current known adverse events listed in the Agent Infor mation section of this protocol; 
• the drug package insert;  
• the current Investigator’s Brochure  
17.2 EXPEDITED REPORTING  
The Site must notify the Central Office and the local IRB within 24 hours of learning of any 
serious adverse events, regardless of attribution, occurring during the study or within 30 days 
of the last administration of the study drug.  A Serious Adverse Ev ent (SAE) MEDWATCH 
form must be completed by the I nvestigator and emailed to the MPN -RC Central Office within 
24 hours of learning of the SAE.  The Site I nvestigator will print and keep a copy of this SAE 
form on file at the study site.  Report serious adv erse events by phone, email, or facsimile to 
the Data Monitor and Clinical Trials Manager:  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 44 of 77   10 Nov 2021  
Confidential  
 
MPN -RC Central Office Phone: (212) 241 -4546  
Fax: (212) 876-5276  
Email:  MPNRC_ClinicalTrialCentralOffice@mssm.edu  
 Central Office personnel is responsible for reporting all SAEs to Celgene via MedWatch to 
drugsafety@celgene.com
. 
At the time of the initial report, the following info rmation should be provided: 
• Study name and IND# 
• Site name or site #  
• Subject ID number 
• A description of the event  
• Date of onset  
• Current status of patient  
• Whether study treatment was discontinued  
• CTCAE grade  
• The reason why the event is classified as serious  
• Investigator assessment of the association between the event and study treatment (if related 
or not and if expected or not) 
Within the following 48 hours, the I nvestigator must provide further information about the 
serious adverse event in the form of a written narrative. This should include an updated Serious 
Adverse Event form, and any other diagnostic information that will assist the understanding of 
the event .  Significant new information on ongoing serious adverse events should be provided 
promptly to the Study Sponsor.  
• The site must notify the central IRB, BRANY, within 5 business days of “any unanticipated 
problems involving risk to subjects or others” (UPR/UPIRSO).  Copies of each report and 
documentation of IRB notification and receipt will be kept in the Clinical Investigator’s 
binder. The IRB should only be notified of a SAE if it meets the definition of “ possibly, 
probably or definitely” related to the study drug, and is an “unexpected” event. 
The following events meet the definition of UPR:  
o Any new information that indicates a new or increas ed risk, or safety issue 
(e.g., Interim A nalysis, S afety Monitoring report, publication, updated S ponsor S afety 
report), that indicates an unexpected change to the risk/benefit ratio for the research.  
o An Investigator Brochure, package insert, or device labeling is revised to indicate an 
increase or magnitude of a previously known risk or  describes a new risk.  
o Withdrawal, restriction, or modification of a marketed approval of a drug, device, or 
biologic used in research protocol 
o Protocol deviation or violation that harmed subjects or others or that indicated subjects 
or others might be at increased risk of harm.  
o Complaint of subject that indicates subjects or others might be at increased risk of harm 
or at risk of a new harm 
o Any breach in confidentiality that may involve risk to the subject or others. 
o Any harm experienced by a subject or other individ ual that in the  opinion of the 
Investigator is unexpected and at least probably related to the research procedures.  
For IND/IDE trials: The Regulatory Agencies (FDA) should be notified within 7 business days 
of any unexpected fatal or life -threatening adverse event with possible relationship to study 
drug, and 15 business days of any event that is considered: 1) serious, 2) unexpected, and 3) at least possibly related to study participation.   
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 45 of 77   10 Nov 2021  
Confidential  
The MPN -RC Data Center and Regulatory Coordinator will receive reports of SAEs through 
the Central Office . The MPN -RC as Study S ponsor shall notify the Regulatory Agencies by 
telephone or by facsimile transmission of any unexpected fatal or life -threatening experience 
associated with the use of the drug as soon as possible but no later than 7 calendar days from 
the S ponsor’s original receipt of the information(1-800-332- 0178) of any unexpected fatal or 
life-threatening experience associated with the use of the drug as soon as possible but no later 
than 7 calendar days from the Sponsor ’s original receipt of the information. All other 
unexpected, serious adverse events that are considered related to study treatment will be 
reported on a MedWatch form by the Study Sponsor to the Regulatory Agencies within 15 
calendar days.  If a previous adverse event that was not initially deemed reportable is later found 
to fit the criteria for reporting, the Study S ponsor will submit the adverse event in a written 
report to the FDA and Health Canada as soon as possible, but no later than 15 calendar days from the time the determination is made.  
17.3  REPORTING GUIDELINES  FOR PHARMACEUTICAL PARTNER  
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of events of being related to e nasidenib  based on the Investigat or Brochure.  In the United 
States, all suspected unexpected serious adverse reactions (SUSARs) will be reported in an 
expedited manner in accordance with 21 CFR 312.32. 
Serious adverse events (SAE) are defined above .  The Central Office  must inform Celgen e in 
writing  using a MEDWATCH 3500A form of any SAE within 24 hours of being aware of the 
event .  The written report must be completed and supplied to Celgene by facsimile within 24 
hours .  The initial report must be as complete as possible, including an assessment of the causal 
relationship between the event and the investigational product(s).  Information not available at 
the time of the initial report (e.g., an end date for the adverse event or laboratory values received 
after the report) must be documented on a follow -up report.  A final report to document 
resolution of the SAE is required.  The Celgene tracking number (XX -XX-XX- PI -#####) and 
the institutional protocol number should be  included on SAE reports (or on the fax cover letter) 
sent to Celgene.   A copy of the fax transmission confirmation of the SAE report to Celgene 
should be attached to the SAE and retained with the patient records. 
Drug Safety Contact Information: 
Celgene Corporation 
Global Dru g Safety and  Risk Management  
86 Morris Avenue  
Building S12 Summit, New Jersey 07901 
Fax: (908) 673-9115 
E-mail: drugsafety@celgene.com
 
 
For any Canadian sub- sites: 
Celgene Inc.  Drug Safety Department  
6755 Mississauga Road, Suite 600 Mississauga, ON  L5N 7Y2  
Telephone: 289-291-4838 
Fax:  289-291-4820 
Email:  drugsafety -canada@celgene.com  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 46 of 77   10 Nov 2021  
Confidential  
17.4 MPN -RC REPORTING OF SUSPECTED UNEXPECTED SERIOUS 
ADVERSE REACTIONS (S USARS) TO REGULATORY BODIES AND 
ETHICS COMMITTEES  
All suspected adverse reactions related to an investigational medicinal product (the tested IMP) 
which occurs in the concerned trial, and that are both unexpected and serious (SUSARs) are 
subject to expedited reporting. These events should be reported by the individual investigators 
to the MPN -RC. 
17.5  MPN -RC REPORTING OF SUSARS  
MPN -RC, or designee, should report all the relevant safety information previously described to 
the concerned Regulatory Agencies. MPN -RC or designee shall inform all investigators 
concerned of relevant information about SUSARs that could adversely affect the safety of 
subjects. All SUSAR reports will also be reported to the FDA and Health Canada.  
17.6  TIMELINES FOR REPORTING  
Fatal or life -threatening SUSARs  
The MPN -RC should notify the Regulatory Agencies as soon as possible but no later than 7 
calendar days after the S ponsor has first knowledge of the minimum criteria for expedited 
reporting. In each case relevant follow -up information should be sought and a  report completed 
as soon as possible.  
Non-fatal and non- life-threatening SUSARs  
All other SUSARs and safety issues must be reported to the Regulatory Agencies as soon as 
possible but no later than 15 calendar days after the S ponsor has first knowledge of  the 
minimum criteria for expedited reporting. Further relevant follow -up information should be 
given as soon as possible.  
17.7 HOW TO REPORT SAFETY  EVENTS  
Minimum criteria for initial expedited reporting of SUSARs  
Information on the final description and evaluation of an adverse reaction report may not be available  within the required time frames for reporting. For regulatory purposes, initial 
expedited reports should be submitted by the Sponsor within the time limi ts as soon as the 
minimum following criteria are met:  
a. a suspected investigational medicinal product,  
b. an identifi able subj ect (e.g. stu dy subject code number ), 
c. an adve rse eve nt assessed as se rious  and unexp ected, and for whi ch the re is a reasonable 
suspec ted ca usal re lationship,  
d. an identifi able reporti ng source, and, when availa ble and a pplicable: 
i. a unique clin ical trial identifi cation number or the  S ponsor' s trial p rotocol c ode 
numbe r) 
ii. a unique case ide ntification (i.e. S ponsor's case identifi cation number ). 
Follow- up reports of SUSARs  
In case of incomplete information at the time of initial reporting, all the appropriate information for an adequate analysis of causality should be actively sought from the reporter or other 
available sources. The Sponsor should report further relevant information after receipt of 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 47 of 77   10 Nov 2021  
Confidential  
follow- up reports. In certain cases, it may be appropriate to conduct follow -up of the long -term 
outcome of a particular reaction. 
 Routine Reporting  
All other adverse events, such as those that are expected or  are unlikely or definitely not related 
to the study participation - are to be reported annually as part of regular data submission.  
18. DRUG INFORMATION  
All study treatments will be administered on an outpatient basis. No investigational or commercial 
agents or therapies other than those described herein may be administered with the intent to treat the patient's malignancy while they are on this study.  
18.1  RUXOLITINIB  
 Ruxolitnib is a JAK inhibitor approved for the treatme nt of patients with MF . It will be dispensed 
commercially, and is available as tablets formulated in 5, 10, 15 and 20 mg strengths. In the US, a 25 mg strength is also available. See the applicable product label (i.e., USPI, Canadian PM or the EMA 
SmPC) fo r more details.  
18.1.1   SIDE EFFECTS  
Reported toxicity of ruxolitinib includes the following:  
• Hemato logic adverse even ts includ e; anem ia, thrombocytope nia and ne utropenia, all of wh ich are 
dose re lated effects.  
• Non-hematologic adverse events include; bruising, di zzine ss, headache, raised ALT, ra ised AST, 
hypercholestero lemia, urinary tract infect ions, we ight ga in, flatulence, herpes zoster, increase in 
systolic blood pressure, const ipation, infection, including Tubercul osis 
18.2  ENASIDENIB   
Enasidenib  tablets are available in 50 -, 100- , 150 - and 200- mg free -base equivalent strength tablets 
for oral administration.  Each tablet is formulated using excipients that are generally regarded as safe 
and are used in marketed drug products.  Celgene Corpora tion will supply 50- mg and 100- mg tablets.  
All tablets will be packaged in high density polyethylene (HDPE) bottles with a desiccant (silica gel) canister and child resistant closures with heat induction seal.  All tablets should be swallowed whole 
and should not be broken or chewed. 
Bottles of enasidenib tablets must be stored according to the package label.  The storage area should 
be secure and have limited access.  Enasidenib tablets will be monitored by the Sponsor for stability 
for the duration of the study.  
18.2. 1  SIDE EFFECTS  
Reported  specific adverse drug reactions of e nasidenib  includ es the fo llowing: 
• Hematologic adverse events include: neutropenia and leukocytosis  
• Non-hematologic adverse events include: IDH -DS  
TLS, GI disturbances (such as nausea, diarrhea, vomiting, and associated dysgeusia and 
decreased appetite), and hyperbilirubinemia.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 48 of 77   10 Nov 2021  
Confidential  
18.2.2   STUDY DRUG PACKAGING  AND LABELING  
Enasidenib tablets will be supplied in high density polyethylene (HDPE) bottles with a 
desiccant  (silica gel) canister, a polyester coil, and child resistant closures with heat induction 
seal.  Packaging and labeling will be prepared to meet all regulatory requirements.  
18.2.3   STUDY DRUG STORAGE  
Bottles of enasidenib tablets must be stored according to the package label. 
All study drug products must be stored in a secure, limited- access location and may be 
dispensed only by the Investigator or by a member of the staff specifically authorized by the 
Investigator.  
18.2.4   RECEIVING DRUG  SUPPLY, RECEIPT AND  STORAGE  
Drug will be distributed from  Celegene to each  participating site . Tablets are to be stored 
according to guidance in drug label insert . 
18.2.5   RETURN OR DESTRUCTIO N OF STUDY DRUG  
Destruction of any remaining study drug will occur according to Mount Sinai Investigational Drug Services’ standard operating procedures.  
18.3  RISKS TO SUBJEC TS 
Adverse events listed in current investigation al brochures  research medications:  
Both ruxolitinib and enasidenib have known side effects profile in patients with myelofibrosis and AML 
respectively. Please refer to to the investigator brochures for detailed listings. 
Known potential side effects from Ruxolitinb  in humans include  the following :   
Hematologic : Anemia (72% to 96%; Grade 3: ≤34%; Grade 4: ≤  11%), Thrombocytopenia (27% to 
70%; Grade 3: 5% to 9%; Grade 4: ≤4%), Neutropenia (3% to 19%; Grade 3: 5%; Grade 4: ≤2%) all of 
which are dose- related effects.  
Non-hematologic : Dizziness (15% to 18%), Headache (15% to 16%), Fatigue (15%), Insomnia (12%), 
Weakness (7%), Bruise (23%), Epistaxis (6%), Pruritus (14%), Increased serum cholesterol (17% to 
35%), Hypertriglyceridemia (15%). Diarrhea (15%), Abdominal pain (15%), Constipation (8%), Nausea (6%), Flatulence (5%), Vomiting. Increased serum ALT (25%; Grade 3: <1%), Increased serum 
AST (17% to 23%). Muscle spasm (12%); Weight gain (≤7%). Dyspnea (13%), Edema (8%), 
Hypertension (<6%). Infection including: Urinary tract infection (≤9%), Her pes zoster (2% to 6%), 
Nasopharyngitis (9%), Cough (8%).  
Known potential side effects from Enasidenib in humans include  the following :   
Non-hematologic : IDH-DS (14%), Noninfectious leukocytosis (8.2%), TLS (5.5%), GI disturbances 
Nausea (50%), Diarrhea (43%), Decreased appetite (34%), Vomiting (34%), Dysgeusia (12%), 
Hyperbilirubinemia (81%). In addition, Febrile neutropenia (23.9%), Pneumonia (14.2%), Sepsis 
(11.8%), Pyrexia (8.5%), Lung infection (6.4%), Acute renal failure (5.5%), and Fatigue (5.2%)  
Based on available pharmacokinetic and drug metabolism data, there are no anticipated major adverse 
reactions that may manifest secondary to drug -drug interactions when enasidenib is utilized 
concomitantly with ruxolitinib; however, there is a potential for  unforeseeable adverse events with  the 
combination.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 49 of 77   10 Nov 2021  
Confidential  
18.3.1   REPRODUCTIVE RISKS  
Patients should not become pregnant or father a baby while on this study. Women should not 
breastfeed a baby while on this study. Females of childbearing potential must either  commit to 
continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at 
least 4 weeks before she starts taking study medications  (enasidenib and ruxolitinib) . Females of 
childbearing potential must also agree to ongoing pregnancy testing. Men must agree to use a condom 
during sexual contact with a female of child bearing potential even if they have had a successful 
vasectomy. All pati ents must be counseled at a minimum of every 28 days about pregnancy 
precautions and risks of fetal exposure.   
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within (4 months), are 
considered immediately reportable events.  IP is to be discontinued immediately. The pregnancy, suspected pregnancy, or positive pregnancy test must be reported to Celgene Drug Safety 
immediately by facsimi le, or other appropriate method, using the Pregnancy Initial Report Form, or 
approved equivalent form. The female subject may be referred to an obstetrician -gynecologist (not 
necessarily one with reproductive toxicity experience) or another appropriate hea lthcare 
professional for further evaluation. 
The Investigator will follow the female subject until completion of the pregnancy, and must notify 
Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.  
If the outcome of the pregnancy was abnormal (e.g., spontaneous or therapeutic abortion), the Investigator should report the abnormal outcome as an AE.  If the abnormal outcome meets any of 
the serious criteria, it must be reported as an  SAE to Celgene Drug Safety immediately by facsimile, 
or other appropriate method, within 24 hours of the Investigator’s knowledge of the event using the 
SAE Report Form, or approved equivalent form. 
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs. In addition, any infant death after 28 days that the Investigator suspects is related to the in utero exposure to the IP should also be reported to Celgene Drug Safety 
immediately by facsimile, or other appropriate method, within 24 hours of the Investigator’s 
knowledge of the event using the SAE Report Form, or approved equivalent form.   
Male Subjects  
If a female partner of a male subject taking investigational product becomes pregnant while the 
male subject is on study treatment or within 4 months of the male subject’s last study treatment, the 
male subject taking IP should notify the Investigator, and the pregnant female partner should be advised to call their healthcare provider immediately.  
CORRELATIVES/ SPECIAL STUDIES  
Submission of samples for correlative studies is mandatory.  The correlative biomarker studies will 
evaluate a series of biomarkers at baseline (at study entry), and during treatment at each study visit, and 
either at the time  of relapse/progression or at termination of study (that is off study drug for any reason).  
Please see  Table 5 for various time points for collection of samples.   
19.1  SHIPPING INSTRU CTIONS  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 50 of 77   10 Nov 2021  
Confidential  
Each site will provide  the necessary  shipping materials  to package .Blood and bone marrow samples 
will be shipped at room temperature on the day  of  collection. All shipments must be sent by overnight 
courier for delivery before 10 AM or morning delivery the next day.   Nail may be sent with the ambient 
shipme nt on the day of collection.  Slides may be batched and shipped every 3 months. In general 
shipments cannot be received on Saturday.  For special arrangements, contact Dr. Weinberg prior to collection of tissue and shipment . 
 
Rona Singer Weinberg, Ph. D 
New York Blood Center 
310 East 67th Street, Room 2-44 
New York, New York 10065 
Phone: (212) 570-3488 
Fax: (212) 570-3495 
rweinberg@nybc.org
 
Laboratory Phone: (212) 570-3412 
Laboratory Fax: (212) 570-3495 
MPDLab@nybc.org  
SAMPLES ARE ACCEPTED MONDAY -THURSDAY 9AM TO 5PM; FRIDAY 9AM TO 1PM.  
NOTE: SAMPLES CANNOT BE RECEIVED ON SATURDAY OR SUNDAY. CALL DR.  WEINBERG 
BEFORE COLLECTING SAMPLES IF SPECIAL ARRANGEMENTS NEED TO BE MADE.   
Include a de -identified copy of the institutional bone marrow aspiration and biopsy report with your 
shipment to the NYBC in New York. This report must include MPN -RC patient ID number, 
differential cell counts on the marrow aspirate, if performed. Contact the central office with any 
questions. 
19.2 BONE MARROW BIOPSY SLIDES  GUIDELINES  
The following samples are to be collected at  screening, at baseline, at  Cycle 4 Day 1  (at the discretion 
of the I nvestigator  for chronic phase patients), at Cycle 7 Day 1 , Cycle 10 Day 1  (at the discretion of 
the Investigator  for chronic phase patients ), after every 6 cycles thereafter, and at termination of study 
for any reason. Biopsies should be done to confirm complete response and when clinically indicated.  
The following bone marrow aspiration and biopsy specimens must be obtained and submitted to Dr. 
Rona Weinberg at the New York Blood Center:  
• three (3) air -dried, unstained bone marrow aspirate slides (if available) 
• four (4) unstained peripheral blood films (thin smear s) 
• two (2) air dried unstained bone marrow biopsy touch preps for patients with no aspirate sample 
(these are made with 8 touches per slide – 4 horizontal touches in 2 rows on the slide)  
Additionally: 
• three (3) unstained paraffin-fixed bone marrow biopsy s lides each containing at least 2 sections  
• one (1) stained H & E biopsy slide  
• one (1) biopsy slide stained for iron  
• one (1) biopsy slide stained with the silver for reticulin fibrosis stain should be submitted for 
confirmatory cytologic and cytochemical s tudies. These should be submitted together with the 
final institutional pathology, cytochemistry, and immuno- phenotyping reports (if possible)  
Bone marrow biopsy should be repeated if relapse occurs or transformation to MDS, or acute leukemia is suspected.  
There must be an adequate amount of marrow biopsy specimen in each smear.  The above requirements are considered minimal.   
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 51 of 77   10 Nov 2021  
Confidential  
Identify each slide with the subject’s patient ID number, protocol number, time point, and type of 
sample.  
The histopathology slid es may be batch shipped every 3 Months to Dr. Weinberg at the NY Blood 
Center.  
Identify each slide with the patient’s MPN -RC patient ID number, protocol number, time point, and 
type of sample.  
Include a de- identified  copy of the institutional bone marrow aspiration and biopsy report with your 
shipment to the NYBC in New York. This report must include MPN -RC patient ID number, 
differential cell counts on the marrow aspirate, if performed. 
19.3  BONE MARROW  ASPIRATE  GUIDELINES  
Bone marrow aspirate sa mples will be c ollected for his topathology, bioma rkers, and 
cytogenet ics/FISH . For biomarkers and cytogenet ics, obtain a to tal of  3-7 m L of aspirated bone  
marrow. Apirate samples collected for biomarkers will be sent to the NYBC on the day of 
collection. Aspirate samples collected for cytogenetics/FISH will be sent to each site’s local 
labs for analysis.  Samples are to be divided a s follows:  
• 2-5 mL of bone marrow aspirate in a green top, hepa rinized tube (BD ca talog number 
366480)  
• 1-2 mL of bone marrow aspirate for Cytogenet ics  
In the event that a biopsy does not produce aspirate, a dditional perpipheral blood sample s must 
be sent for cytogenetic/FISH analysis.   
19.4  PERIPHERAL BLOOD: (USE STERILE TECHNIQUE)  
Peripheral blood samples will be collected at screening, and day 1 of Cycle 1 -Cycle 7, every 3 cycles, 
and at the end of study, in conjunction with standard-of- care blood draws. The total amount to be 
collected should not exceed 25cc (approximately 5 teaspoons).   Peripheral blood samples must be 
shipped ambient on the day of collection. 
• 25 mL of blood: thr ee A CD (yellow top) tubes ( BD catalogue numbe r 364606; 
8.5 mL tubes) 
19.5  NAIL CLIPPINGS  
Two to ten na il clippings are to be obtain ed from each pat ient during the initial entry onto the  protocol. 
Clippings are to be placed in a paper enve lope and the enve lope is to be sealed.   The sealed  envelope 
maybe stored a nd shipped at room temp erature. 
19.6  CYTOGENETIC ANALYSIS  
Diagnostic and follow up cytogenetics will be performed by local institutional laboratories.  All karyotypes will be centrally reviewed (see below).  Samples are to be sent for cytogenetic analysis at screening, at cycle 4 day1 , cycle 7 day 1 , cycle 10 day 1,  every 6 cycles thereafter, and at termination 
of study for any reason.  JPEG or TIFF images must be uploaded into the MPN- RC REDCap database 
for each cytogenetic assessment.  To ensure uniformity of cytogenetic preparations all participating 
local laboratories must adhere to the following requirements established by the central karyotype review 
co-Investigator (Dr. Vesna Najfeld).  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 52 of 77   10 Nov 2021  
Confidential  
19.6.1  GENERAL INCLUSION CRITERIA FOR CONVENTIO NAL 
CYTOGENETICS  
1. Banding level 300 or more and structural aberrations are accepted at 400 or higher banding 
level or confirmed by FISH.  
2. Minimum requirements for baseline assessments:  From each patient, bone marrow (PV, ET) and or unstimulated PB (PMF) specimen must be set up into two, preferably three, different  cultures (direct, 24 hrs. with and without marrow max media). Every effort should 
be made to obtain the growth of cells that are cytogenetically abnormal. 
3. 20 metaphase evaluated from two or more cell cultures or from marrow max culture only.  
4. Only G -banding of chromosomes is acceptable. Other banding methods are not acceptable.  
5. Analysis of cell at 300 band resolution, or low-quality banding, irrespective of the findings, 
to be complemented with FISH screening for subtle aberrations, including del(20)(q11q13) with D20S108 probe. 
6. ISCN 2009 must be used to describe the karyotype. 
7. Aberrations classified as clonal should be present in at least 2 cells by G -banding or 
confirmed by FISH. 
8. Unusual or novel findings should be fully characterized by FISH using appropri ate probes.  
9. Three karyotypes (and metaphase cells) from each patient must be uploaded electronically into the MPN -RC REDCap database to document the stated cytogenetic diagnosis.  The 
karyotypes are uploaded either as TIFF or JPEG files.  
FISH studies, IF P OSSIBLE and warranted in an individual case  
1. Case normal by G banding, if possible, ought to be screened for cryptic changes by 
interphase FISH using a MPN panel of 12 probes: CEP1(1q12)/1q21, 5p15.2/5q31(EGR1), 
CEP7/7q31, CEP8, CEP9/9p21, RB1 at 13q14, P53/CEP17, 20q12/D20S108. 
2. FISH studies are performed on BM or PB on interphase cells processed directly (no culture) 
using Abbott Molecular FISH probes. A minimum of 200 cells at baseline should be scored 
by two individuals. Image of FISH results should be uploaded as JPEG or TIFF file into the MPN -RC database.  
Central Karyotype Review:  Vesna Najfeld, Ph.D., Director, Tumor Cytogenetics, Icahn 
School of Medicine, NY.  
One of the QC indicators  is a proper entry and submission of cytogenetic forms and karyotypes  
by the institutional cytogenetic laboratories. If the local laboratory fails two consecutive 
specimens (poor quality of chromosome banding, missed abnormality, wrong ISCN 
nomenclature) or lack of entering cytogenetic results into MPN - RC, the laboratory w ill be 
informed, and the third failure will result in placing the local laboratory on probation and the institutional PI will be informed. If required, either the central lab in NY or other MPN -RC 
approved cytogenetic lab will perform the studies from the institution whose cytogenetic lab is 
placed on probation. 
For any que stions please call Joe Tripodi PhD, Cytogenetic Res earch Coordina tor, Mount S inai 
Medi cal Center: 212 24 1-8801 or Dr. Vesna N ajfeld at 212 241-8801. 
19.7  SPECIMEN BANKIN G 
Subject samples collected for this study will be retained at New York Blood Center. Specimens will 
be stored indefinitely or until they are used up. If future use is denied or withdrawn by the subject, 
best efforts will be made to stop any additional studies and to destroy the specimens.  
The MPN -RC Consortium’s Tissue Distribution Committee will be responsible for reviewing and 
approving requests for clinical specimen from potential research collaborators outside of the 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 53 of 77   10 Nov 2021  
Confidential  
Consortium. Collaborators will be required to complet e an agreement (a Material Transfer Agreement 
or recharge agreement) that states specimens will only be released for use in disclosed research.  
The specimens, DNA, and their derivatives may have significant therapeutic or commercial value. 
The Informed Consent form contains this information and informs the subject that there is the 
potential for financial gain by the Investigator or a collaborating researcher or entity. Genetic testing 
is a plan for future research.  
The following information obtained from the subject's medical record may be provided to research 
collaborators when specimens are made available:  
• Diagnosis  
• Collection time in relation to study treatment  
• Clinical outcome – if available  
• Demographic data  
Sampling times may be adjusted according t o early trial results in order to optimize evaluation.  No 
additional samples will be collected without formal amendment to this protocol.  Detailed procedures 
for collection, handling, and shipment of samples will be provided in the study Laboratory Manual. 
Samples will be sent to special laboratories at the New York Blood Center for careful study and 
analysis where they will be store using a unique code.   The code linking the sample will be stored at 
Mount Sinai and known only to members of the research t eam at the Central  Coordinating Office.  
Table 5. Correlative Studies Sample Collection Schedule  
 Sample   Baseline  Cycle 1 -6 
Day 1  Cycle 4, 7, 
10, day 1 
and every 
3 cycles4 End of 
study5 Bone Marrow  Aspirate 
Histop athology1
 Three (3) air dried unst ained 
slides  X  X X 
Aspirate 
Cytogenetics2
 At loc al institution, up load 
data and karyotype s to the 
website1
. If no aspirate, 
provide pe ripheral b lood 
karyotypes.  X  X X 
Aspirate 
Biomarke rs3
 2 to 5 mL of bone marrow 
aspirate in a gr een top, 
heparinized tube ( BD catalog 
#366480)  X  X X 
Biopsy 
Histop athology1
 One (1) H&E stain  X  X X 
One (1) Iron st ain X  X X 
One (1) Silve r impr egnate d 
reticulin stain X  X X 
Three (3) Unstain ed paraffin-
fixed slides each with at l east 
2 sections X  X X 
     
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 54 of 77   10 Nov 2021  
Confidential  
 Sample   Baseline  Cycle 1 -6 
Day 1  Cycle 4, 7, 
10, day 1 
and every 
3 cycles4 End of 
study5 
If no aspirate, two ( 2)air dried 
unstained touch p reps, 8 
touches/slide , 2 ho rizontal  X  X X Peripheral Blood  Histop athology1
 Four (4) Unstain ed peripheral 
blood films, th in sm ears X  X X 
Cytogenetics2
 If no BM aspirate karyotypic 
analysis1
 X  X X 
Biomarke rs3
 
Three (3) ACD : yellow 
(BD# 36460 6; 8.5 mL) X X X X Other  
Nails3
 2 to 10 cli ppings 
(pre-treatmen t, at enr ollment 
only) X    
 
1. All slides MUST BE LABELED properly. Labels are to include the patient’s ID number, protocol number, time of study 
(e.g., baseline), type of specimen (e.g., BM biopsy, BM aspirate, blood), type of stain (e.g., Iron, H& E).  For unstained 
slides, use a penc il to label the slides.  All slides are to be sent to Dr. Rona Weinberg at the NYBC in a labeled slide box.  
The label on the box is to include the patient’s ID, protocol number, and time of study.   
2. Cytogenetic analyses are performed as a standard of care.  Karyotypic analysis of unstimulated bone marrow after direct 24 and 48 hours, if available, or peripheral blood shall be performed.  Karyotypic analysis using G -banding technology is 
required.  
3. All tiss ue sam ples must be register ed via the MPN -RC on-line Patient Registration system 
(https://redcap2.mayo.edu/redcap/
 the day they  are collected and prior to shipment. All tubes, and env elopes (nails) 
must be lab eled with patient’s ID numb er, protocol numb er, time of stud y (e.g. b aseline), type of specime n (e.g. BM 
biopsy, BM aspirate,  blood) and d ate o f collection. 
4. BMB is optional for cycles 4 and 10 at the discretion of the I nvestigator  for chronic phase patients  
5. At relapse/progression or termination of study drug (that is off study drug for any reason).  
Fresh blood and bone marrow  are to be stored at ambient temperature and must be shipped 
on the day that they are collected. 
Nails  are to be stored at ambient temperature and may be shipped with the fresh specimens or 
subsequently.  
All slides  are to be shipped to the tissue bank laboratory in a labeled slide box. The label on the 
box is to include the patient’s ID, protocol number, and time point of study. Slides may be 
shipped in batches together with the local institution’s histopathology report, every 3 months.  
All slides are shipped to Dr. Rona Singer Weinberg  at the address above.  
20. STATISTICAL CONSIDERATIONS  
STUDY DESIGN/STUDY ENDPOINTS   
This is a P hase II design to evaluate the efficacy of ruxolitinib and enasidenib combination therapy for 
accelerated or blast- phase MPN patients with IDH2 mutations.  The study will also include a descriptive 
cohort of up to 9 evaluable patients with chronic phase MPN and will utilize a Gehan design in this cohort.  This study will be the first time ruxolitinib and enasidenib wil l be used in combination for this 
patient population. Therefore, the safety of the combination will be confirmed in the first six patients 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 55 of 77   10 Nov 2021  
Confidential  
who are enrolled in the study. If no more than one patient out of the initial six has a treatment- related 
Grade 3 or higher adverse event attributable to the study drugs, the combination therapy will be 
considered safe.  If more than one patient out of the initial six has a limiting toxicity the trial will be 
suspended, and the safety data will be further reviewed.  
20.1 ACCELERATED / BLAST -PHASE COHORT  
Primary endpoint:  The primary endpoint of this study is best overall response, defined as partial response or better (CR+PR+Cri), and will be defined as the best response within 6 c yclesof combination 
therapy. All patients  meeting the eligibility criteria who have signed a consent form and have begun 
treatment will be evaluable for response. Any evaluable patient not meeting the definition for response 
will be deemed as having a non- response.  
Design:  The largest overall r esponse rate where the proposed combination treatment regimen would be 
considered ineffective in this patient population is 5%, and the smallest response rate that would warrant subsequent studies with the proposed regimen is 25%. This is based on retrospe ctive analysis applying 
the 2013 IWG Response Criteria to patients treated with ruxolitinib
1. A Simon’s two- stage minimax 
design will be employed to test the null hypothesis that the true overall response rate in this patient 
population is at most 5%. 
Decision Rule:  Enter 13 patients into the study. If 0 responses are observed in the first 13 patients 
(Stage 1), we may consider this regimen ineffective in the patient population and the trial will close due 
to a lack of efficacy.  If 1 or more responses are observed in th e first 13 evaluable patients, we will 
proceed to Stage 2 and enroll an additional 7 patients onto the study for a total of 20 patients.  After completion of both stages, if 3 or more responses out of the 20 patients are observed, the combination therapy w ill be considered promising for further investigation.  
20.1.2   POWER AND SIGNIFICANCE LEVEL / PRECISION  
Assuming that the number of overall response is binomially distributed, the significance level is <0.10 and the probability of declaring that this regimen warrants further studies (i.e., statistical power) under 
various response proportions can be tabulated as a function of the true response proportion as shown in the following table.  
Table 6. Statistical Power  
Accelerated / Blast -Phase MPN  
If the true response rate is…  0.05 0.10 0.15 0.20 0.25 
Then the probability of early termination of the study is …  0.51 0.25 0.12 0.05 0.02 
Then the probability of declaring that the 
regimen warrants further studies is…  0.07 0.32 0.59 0.79 0.90 
20.2  CHRONIC MPN PHASE  
Primary endpoint:  The primary endpoint of this study is best overall response, defined as clinical 
improvement or better (CI+PR+CR) according to IWG -ELN criteria, and will be defined as the best 
response within 6  cycle s of combination therapy. A ll patients meeting the eligibility criteria who have 
signed a consent form and have begun treatment will be evaluable for response. Any evaluable patient 
not meeting the definition for response will be deemed as having a non- response.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 56 of 77   10 Nov 2021  
Confidential  
Design: Based on a Gehan design, observation of at least 1 response out of 9 evaluable patients would 
indicate activity in this cohort.   This design has 90% power if the true response rate is 25%.   
21. SAMPLE SIZE AND ACCR UAL  
The maximum sample size in the P hase II (accelerated/blast- phase) is 20 evaluable patients.  Allowing 
for enrollment of up to 2 additional patients as replacements for unevaluable  patients  (ineligibility, 
cancellation, major treatment violation, or other reasons) , this study will enroll a maximum of 22 
patients in the Phase II AP/BP cohort.  The maximum sample size in the chronic phase MPN is 9 
evaluable patients.  Allowing for enrollment of up to 1 additional patient as replacement for unevaluable patients, this study will enroll a maximum of 10 patients in the descriptive chronic phase 
MPN cohort.  Therefore,  a maximum total of 32 (22 +10) patients will be enrolled in the trial. 
The anticipated accrual rate is approximately 2 -3 patients per month. Therefore, the accrual period 
for this study is expected to be 15 months. The primary analysis can begin approximately 21 months 
after the trial begins, i.e., as soon as the last patient has been observed for 6 cycles.  
22. DATA ANALYSIS PLANS  
22.1  PRIMARY ENDPOINT  
Overa ll response rate (ORR) :  The overall response rate will be estimated by the number of 
patients that attain a response (defined above per cohort) by 6 cycles of combination therapy 
divided by the total number of treated eligible patients. A two- sided 95% co nfidence interval 
for the true overall response rate will be calculated according the exact binomial method.  
22.2  SECONDARY ENDPOINTS  
To additionally assess the efficacy of the combination of ruxolitinib with e nasidenib  in patients 
with accelerated or blast -phase disease after 6 cycles  of combined therapy using complete 
(CBR) or partial blast response (PBR).  CBR  and PBR will be defined according to Appendix A.  This will be calculated similarly to the primary endpoint f or the MPN -AP/BP cohort. 
To assess the efficacy of the combination of ruxolitinib with enasidenib  in patients with PMF, 
post- PV MF, or post -ET MF in chronic phase and 4- 9% blasts as assessed by the modified 2013 
International Working Group (IWG) Response Criteria, after 6 months of combined therapy. This will be calculated similarly to the primary endpoint for the MPN-AP/BP cohort.  
Adverse events:  All eligible patients that have been initiated treatment will be included in the 
calculation of adverse event rate(s). The maximum grade for each type of adverse event will be 
tabulated for each patient, and frequency tables will be review ed to determine patterns. 
Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.  Adverse events will be summarized overall and by cohort.  
Overall Survival (OS) will be defined as the tim e from firs t treatment with the 
ruxolitinib/enasidenib combination to death by any cause. Patients will be considered censored 
at the last known date alive, if death is not documented. OS will be estimated using the Kaplan -
Meier method . 
22.3  EXPLORATORY/CORRELAT IVE E NDPOINTS  
• Patient -reported symptoms and quality of MF -SAFv4.0 . 
The MF-SAF v4.0 will be scored using published scoring algorithms.  Patient -reported 
symptoms and quality of life (QOL) will be described at each time point using the mean, 95% 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 57 of 77   10 Nov 2021  
Confidential  
confidence interval, median, and range. Changes from baseline will also be described using the 
mean, 95% confidence interval, median and range, and assessed using paired t -tests or 
Wilcoxon signed- rank tests as appropriate. Graphical procedures will include plots of average 
values over time.  .  
• Biomarkers:  
Biomarkers will be described at each time point using the mean, 95% confidence interval, 
median, and range if continuous, or frequency and relative frequency if binary. Continuous 
changes from baseline will be described using the mean, 95% confidence interval, median and 
range, and assessed using paired t -tests or Wilcoxon signed -rank tests as appropriate.  Binary 
changes from baseline will be described using frequencies and relative frequencies and  assessed 
using M cNemar’s tests as appropriate.  Biomarker associations with response (IWG/ELN 
and/or bone marrow) will be primarily descriptive in nature given the small sample size.  
23. STUDY MANAGEMENT  
23.1  CONFLICT OF INT EREST  
Any research personnel who has a conflict of interest with this study (patent ownership, intellectual 
property, royalties, or financial gain greater than the minimum allowable by their institution, etc.) must 
declare their conflict of interest to the appropriate institutional review bodies. Local institutional conflict 
of interest policies will be followed for all research personnel associated with the research project.   
23.2  INSTITUTIONAL REVIEW  BOARD (IRB) APPROVAL AND 
CONSENT  
It is expected that the IRB  will have the proper representation and function in accordance with 
federally mandated regulations. The IRB must approve the consent form and protocol. 
In obtaining and documenting informed consent, the I nvestigator should comply with the applicable 
regul atory requirement(s) and should adhere to Good Clinical Practice (GCP) and to ethical principles 
that have their origin in the Declaration of Helsinki.  
Before recruitment and enrollment onto this study, the patient will be given a full explanation of the 
study and will be given the opportunity to review the consent form. Each consent form must include 
all the relevant elements currently required by the FDA Regulations and local or state regulations. Once this essential information has been provided to the p atient and the Investigator is assured that 
the patient understands the implications of participating in the study, the patient will be asked to give 
consent to participate in the study by signing an IRB-approved consent form. 
Prior to a patient’s particip ation in the trial, the written informed consent form should be signed and 
personally dated by the patient and by the person who conducted the informed consent discussion. A 
copy of the signed consent form should be provided to the patient. 
24. DATA MANAGEMENT AND MONITORING/ AUDITING  
24.1  DATA MONITORING COMM ITTEE/DATA SAFETY MO NITORING 
BOARD (DMC/DSMB)  
This trial will be monitored by the MPN -RC Data Safety Monitoring Board according to the established 
Charter.   
An External Data and Safety Monitoring Board has been established. All members have experience and 
expertise in clinical trials. DSMB members are not directly involved in any phase of MPN -RC clinical 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 58 of 77   10 Nov 2021  
Confidential  
trials and they have no major financial or intellectual conflict of interest that would prevent them  from 
objectively reviewing the interim data and providing advice to the Trials Steering Committees and the 
Clinical Advisory Group. They function independently of all other individuals, processes, and progress to ensure study integrity, monitor patient sa fety (providing quarterly safety reports), evaluate the results 
of interim analysis to assess efficacy, and make recommendations about protocol amendments and early termination to the Trials Steering Committees. The External Data Safety and Monitoring Boar d must 
meet at least two times a year.  
24.2  MEDICAL MONITORING  
It is the responsibility of the local institutional Principal Investigator to oversee the safety of the study 
at his/her site. This safety monitoring will include careful assessment and appropr iate reporting of 
adverse events as noted above, as well as the construction and implementation of a site data and safety -
monitoring plan.  Medical monitoring will include a regular assessment of the number and type of serious adverse events.  
24.3  MONITORING PLAN AND PERIOD OF OBSERVATIO N 
The MPN -RC will monitor study progress on an on -going basis; this will include electronic and 
telephone correspondence between the central coordinating office and with individual investigators 
and/or their designee s at other sites.  
The Sponsor or the Sponsor designees, “study monitors,” will monitor the study according to a predetermined monitoring plan (centrally and with on- site visits). The monitoring visit will provide the 
Sponsor with opportunity to: 
• Evaluate t he progress of the study 
• Verify the accuracy and completeness of CRFs  
• Assure that all protocol requirements, applicable laws and/or regulations, and Investigator’s obligations are being fulfilled  
• Resolve any inconsistencies in the study records 
25. REGULATORY REQUIREME NTS  
See the Regulatory Requirements section for a listing of required regulatory documents.  All protocol 
amendments will be generated through and distributed by the MPN -RC Central Coordinating Office, 
which will also maintain records of IRB approval, amendments, SAEs, and annual reviews.  
25.1  ADHERENCE TO THE PRO TOCOL  
Except for an emergency situation in which proper care for the protection, safety, and well -being of the 
study subject requires alternative treatment, the study shall be conducted exactly as described in the 
approved protocol.  
25.2  EMERGENCY MODIFICATI ONS  
Investigators may implement a deviation from, or a change of, the protocol to eliminate an immediate  
hazard(s) to trial subjects without prior IRB approval.  
25.3  OTHER REPORTABLE NEW  INFORMATION AND PRO TOCOL 
DEVIATIONS/VIOLATIONS  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 59 of 77   10 Nov 2021  
Confidential  
In accordance with BRANY  IRB  requirements, the following information must be reported within five 
(5) business days:  
• Non-compliance with federal regulations governing human research or with the 
requirements or determinations of the IRB, or an allegation of such non- compliance.  
• Failure to follow the protocol due to the action or inaction of the Investigator or research 
staff.  
• Breach of confidentiality  
• Premature suspension or termination of the research by the Sponsor or I nvestigator.  
25.4 AMENDMENTS TO THE PR OTOCOL  
Should amendments to the protocol be required, the amendments will be originated and documented by 
the Principal Investigator. It should also be noted that when an amendment to the protocol substantially 
alters the study design or the potential risk to the patient, a r evised consent form might be required.  
The written amendment, and if required the amended consent form, must be sent to the IRB for approval 
prior to implementation.  
 
25.5  RECORD RETENTION  
Study documentation includes all Case Report Forms, data correction forms or queries, source 
documents, Sponsor- Investigator correspondence, monitoring logs/letters, and regulatory documents 
(e.g., protocol and amendments, IRB correspondence and approval, signed patient consent forms). 
Source documents include all recor dings of observations or notations of clinical activities and all 
reports and records necessary for the evaluation and reconstruction of the clinical research study.  
Government agency regulations and directives require that the Study I nvestigator must retain all study 
documentation pertaining to the conduct of a clinical trial. In the case of a study with a drug seeking 
regulatory approval and marketing, these documents shall be retained for at least two years after the 
last approval of marketing application in an International Conference on Harmonization (ICH) region. 
In all other cases, study documents should be kept on file until three years after the completion and 
final study report of this investigational study.  
26. OBLIGATIONS OF INVES TIGATORS  
The Principal Investigator is responsible for the conduct of the clinical trial at the site in accordance 
with Title 21 of the Code of Federal Regulations and/or the Declaration of Helsinki. The Principal 
Investigator is responsible for personally overseeing the treatment of all study patients. The Principal 
Investigator must assure that all study site personnel, including Sub-I nvestigators and other study 
staff members, adhere to the study protocol and all FDA/GCP/NCI regulations and guidelines regarding clin ical trials both during and after study completion. 
The Principal Investigator at each institution or site will be responsible for assuring that all the 
required data will be collected and entered onto the Case Report Forms. Periodically, monitoring 
visits  will be conducted and the Principal Investigator will provide access to his/her original records 
to permit verification of proper entry of data. At the completion of the study, all case report forms will be reviewed by the Principal Investigator and will require his/her final signature to verify the 
accuracy of the data.  
26.1  GOOD CLINICAL PRACTI CE 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 60 of 77   10 Nov 2021  
Confidential  
The study will be conducted in accordance with the International Conference on Harmonization  
(ICH) for Good Clinical Practice (GCP) and the appropriate regulatory requirement(s).  The 
Investigator should be thoroughly familiar with the appropriate use of the study drug as 
described in the protocol and Investigator’s Brochure.  Essential clinical documents should be 
maintained to demonstrate the validity of the study and the integrity of the data collected.  
Master files should be established at the beginning of the study, maintained for the duration of 
the study and retained according to the appropriate regulations.  
26.2  ETHICAL CONSIDERATIO NS 
This study is to be conducted according to US and international standards of Good Clinical 
Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), 
applicable government regulations and Institutional research policies and procedures.  
This pro tocol and any amendments should be submitted to a properly constituted independent 
EC or IRB, in agreement with local legal prescriptions, for formal approval of the study conduct.  The decision of the EC/IRB concerning the conduct of the study should be m ade in 
writing to the I nvestigator and a copy of this decision should be provided to the MPN -RC 
Central Office before commencement of this study.  The Investigator should provide a list of 
EC/IRB members and their affiliate to the MPN -RC Central Office.  
All subjects for this study will be provided a consent form describing this study and providing 
sufficient information for subjects to make an informed decision about their participation in this 
study.  This consent form should be submitted with the protocol  for review and approval by the 
EC/IRB for the study.  The consent of a subject, using the EC/IRB -approved consent form, 
must be obtained before a subject is allowed to participate.  This consent form must be signed by the subject or legally acceptable surrogate, and the Investigator obtaining the consent.  
26.3  PATIENT INFORMATION AND INFORMED CONSENT  
After the study has been fully explained, written informed consent should be obtained from either the patient or his/her guardian or legal representative prio r to study participation. The 
method of obtaining and documenting the informed consent and the contents of the consent should comply with ICH-GCP and all applicable regulatory requirement(s). 
26.4  PATIENT CONFIDENTIAL ITY  
Information about study subjects should be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
Those regulations require a signed subject authorization informing the subject of the following: 
• What protected  health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
The patient has the right to revoke their authorization for use of their PHI. In the event that a 
subject revokes authorization to collect or use PHI, the I nvestigator, by regulation, retains the 
ability to use all information collected prior to the revoca tion of subject authorization.  For 
subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their 
scheduled study period. 
26.5 PROTOCOL COMPLIANCE  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 61 of 77   10 Nov 2021  
Confidential  
The Investigator should conduct the study in compliance with the protocol given 
approval/favorable opinion by the IRB and the appropriate regulatory authority(ies). Changes 
to the protocol will require approval of the MPN -RC and written IRB approval/favorable 
opinion prior to implementation, except when the modification is needed to eliminate an 
immediate hazard(s) to patients.  The MPN -RC will submit all protocol modifications to the 
regulatory authority(ies) in accordance with the governing regulations. Any departures from the protocol must be fully documented in the source documents. 
26.6 MANAGEMENT OF INFORM ATION  
The MPN -RC at Mount Sinai will maintain sponsorship authority at the Icahn School of 
Medicine at Mount Sinai School and all other participating sites.  
Eligibility criteria will be confirmed using the electronic CRF. All inclusion and exclusion 
criteria are listed; the I nvestigator is obliged to fill in all items. Subjects are enrolled in the 
study only if he/she fulfills all inclusion and no exclusion criteria. 
IRB approval for each site will be submitted to the MPN -RC Central Coordinating Office via 
e-mail (PDF file preferred) or fax:  
MPN -RC Central Coordinating Office  
Clinical Trials Manager  
MPN -RC Central Office  
Phone: ( 212) 241-4546 
Fax: (212) 876-5276 
Email: MPNRC_ClinicalTrialCentralOffice@mssm.edu  
Office hours: Monday through Friday 9AM to 5PM EST/EDT 
Upon receipt of these documents and confirmation of certification of the Study I nvestigators, 
the site will be granted  access to the online registration system and case report forms. 
In addition, all protocol amendments will be generated through and distributed by the MPN -RC 
Central Coordinating Office, which will also maintain records of IRB approval, amendments, SAEs, a nd annual reviews. 
Serious adverse event reporting is detailed in the Reporting Requirement section of this 
protocol. 
Protocol deviations will be reported to the MPN -RC Data Monitor and CTM:  
CTM: Lonette Sandy 
Tel: (212) 241-4546 
Email: lonette.sandy@mssm .edu 
Office hours: Monday through Friday 9AM to 5PM (EST) 
 
Data Monitor: Melissa Nashawati  
Tel: (210) 450-3955 
Email: nashawati @uthscsa.edu
 
Office hours: Monday through Friday 8:00AM to 5:00 PM (CT)  
The MPN -RC Principal Investigators will be notified as soon as possible (and within 7 days) 
of reporting and will be responsible for granting approval. 
The MPN -RC will monitor study progress on an on- going basis; this will include electronic and 
telephone correspondence between the central coordinating office and with individual 
investigators at other sites.  
26.7  DRUG ACCOUNTABILITY  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 62 of 77   10 Nov 2021  
Confidential  
Accountability for the study drug at all study sites is the responsibility of the site P rincipal 
Investigator.  The responsibl e Investigator at each participating center will ensure that the study 
drug is used only in accordance with this protocol, drug accountability records indicating the 
drug’s delivery date to the site, inventory at the site, use by each patient, and return.  
Accountability records will include dates, quantities, lot numbers, expiration dates (if applicable), and patient numbers. Conditions of the excursion will be evaluated on a case by 
case basis and a memo indicating continued use or discontinuation of the drug product involved 
will be communicated.  
26.8  SOURCE DOCUMENTS  
Source data includes all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the tria l. Source 
data are contained in source documents. Examples of these original documents, and data records 
include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies or transcriptions certified after verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or  magnetic  media, x- rays,  subject files, and 
records kept at the pharma cy, at the laboratories, and at medico -technical departments involved 
in the clinical trial.  
26.9  CASE REPORT FORMS (C RF)  
The study CRF is the primary data collection instrument for the study.  All data requested on 
the CRF must be recorded. The CRFs may be found online at the MPN -RC website at 
(https://redcap2.mayo.edu/redcap/).  The CRF Form Submission schedule is listed below:  
Table 7.  CRF Form Submission Schedule  
MPN -RC 
#119 Form#  MPN -RC #119 FORM 
NAME  CRF SUBMISSION SCHEDULE  
00 Recruitment Form  At Registration  
01 Baseline  After Registration  
02 Bone Marrow Report At required time points  specified in 
Table 5. 
03 Cytogenetic  At required time points  specified in 
Table 5. 
04 Symptom Assessment Package At required time points  specified in 
Table 4. 
05 Drug Dosage form At required time points  specified in 
Table 4. 
06 Adverse Event form  At occurrence of Adverse Event 
07 Cycle 1 -2 Day 1 CRF  At Cycle 1 -2 Day 1  
08 Cycle 1 -2 Day 8 CRF  At Cycle 1 -2 Day 8  
09 Cycle 1 -2 Day 15 CRF  At Cycle 1 -2 Day 15  
10 Cycle  1-2 Day 22 CRF  At Cycle 1 -2 Day 22  
11 Cycle 3+ every Day 1 CRF  At Cycle 3+ Day 1  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 63 of 77   10 Nov 2021  
Confidential  
MPN -RC 
#119 Form#  MPN -RC #119 FORM 
NAME  CRF SUBMISSION SCHEDULE  
12 Off Treatment  At time of treatment withdrawal  
13 Off Study  At time of off study, 30 days post 
treatment withdrawal  
26.10  PREMATURE CLOSURE OF  THE STUDY  
This study may be prematurely terminated, if in the opinion of the MPN -RC Trial Steering 
Committee there is sufficient reasonable cause. Written notification documenting the reason 
for study termination will be provided to the Investigator by the terminating party.  
Circumstances that may warrant termination include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to patients 
• Failure to enter patients at an acceptable rate  
• Insufficient adherence to protocol requirements  
• Insufficient complete and/or evaluable data  
• Plans to modify, suspend or discontinue the development of the study drug 
26.11  RECORD RETENTION  
It is the Investigator’s responsibility to retain study essential documents for at least 2 years after 
the last approval of a marketing application in their country and until there are no pending or 
contemplated marketing applications in their country or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigatio nal product.  These 
documents must be retained at least 2 years following completion of the last follow -up on 
patients on active study.  These documents should be retained for a longer period if required by 
an agreement with the Sponsor.  In such an instance, it is the responsibility of the Sponsor to 
inform the Investigator/institution as to when these documents no longer need to be retained. 
26.12  DATA MANAGEMENT  
Study data will be recorded and managed using the Research Electronic Data Capture (REDCap) s ystem developed by Vanderbilt University.  Research Electronic Data Capture is a 
secure, web -based application designed to support data capture for research studies, 
providing:1) an intuitive interface for validated data entry; 2) audit trails for tracking  data 
manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external 
sources.   
After IRB approval and site training, REDCap database access will be given to approved and 
trained individuals at each site.  Each user will have a unique username/password assigned by 
the REDCap administrator at Mayo Clinic (where the MPN -RC Statistical and Data Center 
Core is located).  
26.13  QUALITY ASSURANCE  
Weekly registr ation reports will be generated to moni tor patient accruals and comp leteness o f 
registr ation data. Routine data qua lity reports w ill be generat ed to assess  missing data and 
inconsistenci es. Accrual rates and extent and accuracy  of evaluations and follow-up will be monit ored 
periodi cally throughout the study period and potenti al probl ems will be brought to t he at tention o f the 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 64 of 77   10 Nov 2021  
Confidential  
study team for di scuss ion and action. Monthly tel econferences including the P rincipal Inv estigato rs 
and/or th eir designe es from all sit es will be h eld to expedite the reviews of toxicity and eff icacy  data. 
27. WITHDRAWAL OF SU BJECTS  
Treatment  with study drugs is to be di scontinued  when any of the fo llowing occu rs: 
• Lack  of any r esponse  by 6 cycles of comb ined enasidenib  and ruxo litinib therapy (any e ffort should 
be made to provide therapy to the patient in a safe w ay for at lea st 3-6 cycl es for proper a ssessment 
of potenti al efficacy). 
• Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or 
which rule out continuation of study drug 
• Withdrawal of consent  
• Lost to follow up 
• Toxicity requiring dose modification/treatment suspension, without recovery to baseline, in a patient with less than a CRi  
• Death  
 
The patie nt will have an end of study visit at  30 days af ter discont inuat ion of the proto col treatment 
±7 days to  assess for AEs. 
28. BREACH OF CONFIDENTI ALITY  
 
One of the risks is relea se of information from healt h or r esearch records i n a way that violates privacy 
right s. The investigators wil l prot ect recor ds so  that name, addres s, phone n umber, and any other 
inform ation tha t identifies the participa nt will be kept private. I t will be s tated to the participa nt that the 
chance that this information w ill be given t o an unauthorized in dividua l without t he participa nt’s 
permission is v ery small. 
29. POTENTIAL BENEFITS TO SUBJECTS  
We hypothesiz e that the combinati on of ruxolitinib and enasidenib in patients with MPN both in 
accelerate/blasts- phase as well as with high risk chronic phase myelofibrosis with an IDH2 mutation will 
improve the ov erall clinical response to therapy including complete response, partial response, complete and 
partial blasts response, symptomatic improvement and improvement in quality of  life. 
30. SHARING OF RESULTS W ITH SUBJECTS  
Results of tests performed during the study will be shared with the subject. Results of biomarker 
correlates will not be shared.  
31. PRIOR APPROVALS  
Approval to commence research will be obtained initially at Mount Sinai through the usual protocol 
approva l pathway including the Disease Focus Group, Resource Allocation and Evaluation, Protocol 
Review and Monitoring Committees. Once this is complete, the protocol will be submitted for an IND 
to the Food and Drug Administration.  The IND -approved protocol wil l then be submitted to the central 
SMART IRB (BRANY) for ethical and regulatory evaluation.  Once this is IRB approved the final contract (with budget) will be executed and a Site Initiation  Visit (SIV) will be scheduled. This will 
then allow for Mount Sinai to activate the protocol and start enrollment. The BRANY approved protocol 
will be concurrently submitted for internal review at the other MPN -RC participating sites. SIVs will 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 65 of 77   10 Nov 2021  
Confidential  
be scheduled at each site once the protocol is approved locally. This will be c oordinated throughout the 
MPN -RC central office within Project 4.  
32. ECONOMIC BURDEN TO S UBJECTS  
There will be no additional costs to the subject to participate in the study beside the standard of care 
costs. Research related per patient costs will be covered by the MPN -RC and will be determined by 
Medicare Analysis review (MCA).   
33. CONSENT PROCESS  
Before protocol -specified procedures are carried out, consenting professionals will explain full details 
of the protocol and study procedures as well as the risks involved to participants prior to their inclusion in the study. Participants will also be informed that they are free to withdraw from the study at any time. 
All participants must sign an IRB/PB -approved consent form indicating their consent to participate. 
This consent form meets the requirements of the Code of Federal Regulations and the Instit utional 
Review Board/Privacy Board of each site. The consent form will include the following:  
1. The nature and objectives, potential risks and benefits of the intended study.  
2. The length of study and the likely follow-up required. 
3. Alternatives to the propos ed study. (This will include available standard and investigational 
therapies. In addition, patients will be offered an option of supportive care for therapeutic studies.) 
4. The name of the I nvestigator(s) responsible for the protocol.  
5. The right of the participant to accept or refuse study interventions/interactions and to withdraw from 
participation at any time.  
Before any protocol -specific procedures can be carried out, the consenting professional will fully 
explain the aspects of patient privacy concerning research specific information.   
Each participant and consenting professional will sign the consent form. The participant must receive a 
copy of the signed informed consent form. The consent process should be documented in the patients’ 
medical records.  
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 66 of 77   10 Nov 2021  
Confidential  
34. REFERENCES  
1. Pieri L, Sant'Antonio E, Rumi E, et al. IWG -MRT 2013 Criteria -Based Assessment of Response 
Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers. 
2015;126(23):1615- 1615.  
2. Arber D A, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization 
classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391- 2405.  
3. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population -based incidence and 
survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976- 1995. American journal of hematology. 1999;61(1):10- 15. 
4. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88(3):1013- 1018.  
5. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255- 1265.  
6. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single -institution experience with 91 cases. Blood. 
2005;105(3):973- 977. 
7. Masarova L, Bose P, Newberry K, et  al. Correlation between blast percentage in myelofibrosis and 
outcomes: A single -center experience. 2017;35(15_suppl):e18562- e18562.  
8. Mascarenhas J. Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis. Hematology American Society of Hematology Education Program. 2015;2015:329- 339. 
9. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short- lived' and 'long -lived' patients at 
presentation of idiopathic myelofibrosis. British journal of haematology. 1997;97(3):635 -640. 
10. Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer. 
2007;109(10):2083- 2088.  
11. Cervantes F, Duprie z B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis 
based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895- 2901.  
12. Mascarenhas J. 
Risk adapted approach to the treatment of primary myelofibrosis . In: 
Association EH , ed. Hematology Education . Vol 14.2009: 192-199 . 
13. Mesa RA. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003. Current hematology reports. 2003;2(3):264- 270. 
14. Hoffman R, Rondelli D. Biology and treatment of primary myelofibrosis. Hematology American Society of Hematology Education Program. 2007:346- 354. 
15. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lance t (London, England). 2005;365(9464):1054- 1061.  
16. Kralovics R, Passamonti F, Buser AS, et al. A gain -of-function mutation of JAK2 in myeloproliferative 
disorders. N Engl J Med. 2005;352(17):1779- 1790.  
17. James C, Ugo V, Le Couedic JP, et al. A unique clo nal JAK2 mutation leading to constitutive 
signalling causes polycythaemia vera. Nature. 2005;434(7037):1144- 1148.  
18. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, an d myeloid metaplasia with myelofibrosis. Cancer 
cell. 2005;7(4):387- 397. 
19. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379- 2390.  
20. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391- 2405.  
21. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasm s. 
Leukemia. 2009;23(11):2183- 2186.  
22. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5):905- 911. 
23. Schaub FX, Looser R, Li S, et a l. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can 
be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003- 2007.  
24. Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibro sis. Blood 
advances. 2016;1(2):105- 111. 
25. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861- 1869.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 67 of 77   10 Nov 2021  
Confidential  
26. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrim ental mutations and 
prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28(9):1804-
1810.  
27. Verstovsek S, Mesa RA, Gotlib J, et al. A double -blind, placebo- controlled trial of ruxolitinib for 
myelofibrosis. N Engl J Med. 2012;366(9):799- 807. 
28. Harrison C, Kiladjian JJ, Al- Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy 
for myelofibrosis. N Engl J Med. 2012;366(9):787- 798. 
29. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long -term outcom es of 107 patients with myelofibrosis 
receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical 
controls. Blood. 2012;120(6):1202- 1209.  
30. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with 
myelofibrosis: results of a median 2 -year follow -up of COMFORT -I. Haematologica. 
2013;98(12):1865- 1871.  
31. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three- year efficacy, safety, and survival findings from 
COMFORT -II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. 
Blood. 2013;122(25):4047- 4053.  
32. Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR -ABL - myeloproliferative neoplasms. Blood. 2008;112(5):1628- 1637.  
33. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with 
JAK2V617F. Leukemia. 2012;26(3):475- 480. 
34. Rampal R, Ahn J, Abdel -Wahab O, et al. Genomic and functional analysis of leukemic transformation 
of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States 
of America. 2014;111(50):E5401- 5410.  
35. Lee YC, Hsieh CC, Lee YL, Li CY. Molecular Markers and Prognosis of Myelofibrosis in the 
Genomic Era: A Meta -analysis. Clinical lymphoma, myeloma & leukemia. 2018;18(9):558 -568. 
36. Ward PS,  Patel J, Wise DR, et al. The common feature of leukemia -associated IDH1 and IDH2 
mutations is a neomorphic enzyme activity converting alpha -ketoglutarate to 2 -hydroxyglutarate. 
Cancer cell. 2010;17(3):225- 234. 
37. Marcucci G, Maharry K, Wu YZ, et al. IDH1  and IDH2 gene mutations identify novel molecular 
subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 
2010;28(14):2348- 2355.  
38. Dang L, White DW, Gross S, et al. Cancer -associated IDH1 mutations produce 2- hydroxyglutarate. 
Nature. 2009;462(7274):739- 744. 
39. Figueroa ME, Abdel -Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a 
hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer 
cell. 2010;18(6):553- 567. 
40. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block 
to cell differentiation. Nature. 2012;483(7390):474 -478. 
41. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058- 1066.  
42. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic pro filing in acute 
myeloid leukemia. N Engl J Med. 2012;366(12):1079- 1089.  
43. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722- 731. 
44. Luesink M, Jansen JH. Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. British journal of haematology. 2010;151(3):209- 220. 
 
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 68 of 77   10 Nov 2021  
Confidential  
34.1  APPENDIX A: RESPONSE  CRITERIA  
 
Complete Response  As per 2013 IWG -MRT and ELN Criteria  
Partial Response  As per 2013 IWG -MRT and ELN Criteria  
Clinical Improvement 
(CI) As per 2013 IWG -MRT and ELN Criteria  
Anemia Response  As per 2013 IWG -MRT and ELN Criteria  
Spleen Response  As per 2013 IWG -MRT and ELN Criteria  
Symptom Response  As per 2013 IWG -MRT and ELN Criteria  
Progressive Disease  After at least 3 cycles of combined therapy:  
• New splenomegaly that is palpable at least 5cm below the LCM  
• a ≥100% increase in palpable distance, below LCM, for baseline 
splenomegaly of 5 -10cm or  
• a 50% increase in palpable distance, below LCM, for baseline 
splenomegaly of > 10cm  
• Progression from chronic -phase disease (<  10% blasts) to blast -phase 
(≥ 20% blasts) disease  on two separate CBCs within 28 days  
• For patients in accelerated of blast phase disease at baseline, a doubling of 
the absolute blast count  
Stable Disease  As per 2013 IWG -MRT and ELN Criteria  
Cytogenetic Remission  As per 2013 IWG -MRT and ELN Criteria  
Molecular Remission  • Complete Molecular remission: eradication of IDH2  and 
JAK2/MPL/CALR  mutations as assessed by both next -generation 
sequencing and digital PCR assays.  
• Partial Molecular remission: 50% reduction in mutant IDH2  and 
JAK2/MPL/CALR  allele burden as assessed by next -generation sequencing  
Cytogenetic/Molecular  
Relaps e As per 2013 IWG -MRT and ELN Criteria  
Complete Blast Response  Absence of circulating peripheral blood blast count with residual features of 
chronic -phase MPN maintained for at least 28 consecutive days.   
Partial Blast Response  Reduction to <  4% blast count in peripheral blood with residual features of 
chronic -phase MPN maintained for at least 28 consecutive days.   
 
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 69 of 77   10 Nov 2021  
Confidential  
34.2  APPENDIX B : IWG -MRT AND ELN RES PONSE CRITERIA  
 
 
 
  

A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 70 of 77   10 Nov 2021  
Confidential  
34.3 APPENDIX C:   MEDICATIONS KNOWN TO  PROLONG THE QT 
INTERVAL  
 
amiodarone  citalopram  Escitalopram  methadone  sevoflurane  
astemizole  clarithromycin  Flecainide  moxifloxacin sotalol  
azithromycin  disopyramide Halofantrine pentamidine sparfloxacin  
bepridil dofetilide  Haloperidol  pimozide terfenadine  
chloroquine  domperidone Ibutilide  probucol thioridazine 
chlorpromazine  droperidol Levomethadyl  procainamide  
cisapride erythromycin  Mesoridazine  quinidine  
 
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 71 of 77   10 Nov 2021  
Confidential  
34.4 APPENDIX D:   GUIDANCE  IDH -INHIBITOR DIFFER ENTIATION 
SYNDROME (IDH -DS) GU IDANCE FOR MANAGEMENT OF 
DIFFERENTIATION SYNDROME IN SUBJECTS WITH HEMATOLOGIC 
MALIGNANCIES TREATEDWITH IDH -INHIBITORS  
The participating investigators/health care professionals are responsible for the appropriate 
evaluation and management of the safety related issues in subjects enrolled in the study. The approach outlined below for identifying and managing Differentiation Syndrome in patients treated with IDH inhibitors should be considered as guidance and therefore management of each case should be individualized, as appropriate. 
Introduction to IDH inhibitors Differentiation  Syndrome  
The isocitrate dehydrogenase (IDH) mutation, found in up to 15% of subjects with AML36,37, leads to 
excess accumulation of 2 -hydroxyglutarate (2- HG) that causes inhibition of dioxygenase dependent 
enzymes responsible for demethylation of DNA and histones, and consequently resulting in impaired 
bone marrow differentiation39,40. 
Direct inhibition of mutated protein activity by IDH inhibitor is intended to block abnormal product ion 
of the oncogenic metabolite 2- HG and impact clinical outcome through a variety of mechanisms that 
include restoration of differentiation of the malignant cells.  
In patients with hematologic malignancies, initiation of treatment with the differentiating  agents, such 
as IDH inhibitors, and associated maturation of aberrant bone marrow, may alter the balance of the 
expression of adhesion molecules and chemoattractants (cytokines) that could mediate tissue infiltration by maturing blood cells
44, associated with signs and symptoms of Differentiation Syndrome (DS).  
Signs and symptoms could include fever, dyspnea, edema/ weight gain, increased serum creatinine and, in some cases, clinical  features consistent with the acute respiratory distress syndrome with associated 
bilateral pulmonary infiltrates, and pulmonary or pericardial effusions. Increases in white blood cell (WBC) count concurrent to DS has been observed, but by itself do not substantiate the syndrome.   
There is no pathognomonic clinical sign or laboratory test to diagnose DS. In some instances, clinical 
presentation of DScan be confounded by other medical condition(s), such as concurrent infections or 
heart failure. Consequentl y, diagnosis of DS is made by excluding other potential causes, rather than 
based on a specific set of signs and symptoms.  
To improve diagnostic and treatment practices for management of DS associated with treatment with 
IDH-inhibitors (IDH DS), data for adverse events meeting diagnostic criteria for DS will be reviewed 
and assessed by a Differentiation Syndrome Review Committee.  
Clinical Assessment of Subjects for signs and symptoms of IDH -inhibitors differentiation 
syndrome  
Due to the heterogeneity of clinical symptoms and differences in adverse events reporting practices (e.g., symptoms of suspected IDH DS reported in place of DS diagnosis), exact incidence of 
Differentiation Syndrome in subjects treated with IDH- inhibitors has not been determined. In the 
clinical trial conducted for Idhifa’s approval, at least 14 percent of patients experienced differentiation 
syndrome
 
As it has been reported by the Study I nvestigators, IDH DS is more likely to manifest within 10 days to 
5 months after the start of treatment, or after re- initiation of the study drug following prolonged 
treatment interruption (e.g., >3 weeks) in subjects who are not in complete remission.  In some cases, 
symptoms re- appeared after cessation of treatment for th e initial manifestation of IDH DS.  
Signs and Symptoms  
In clinical trials with IDH inhibitors, DS has  been described in two categories of severity: 
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 72 of 77   10 Nov 2021  
Confidential  
Severe IDH -Differentiation Syndrome  
Based  on presence of any of the below listed factors, with, or without symptoms of moderate severity 
IDH DS  
• New or worsened progressive dyspnea; hypoxia with increasing demands for supplemental oxygen; 
respiratory distress, without definitive etiology or refra ctory to treatment for the initially suspected 
cause  
• Radiologic evidence of new or worsened bilateral pulmonary involvement (infiltrates or opacities) with or without presence of infection, refractory to treatment with anti- infectives (antibiotics, 
antivi rals, antifungals) that was not attributed to another cause  
• Radiologic evidence of new or worsened pleural or pericardial effusion that has no definitive 
etiology or is refractory to treatment fo r the initially suspected cause.  
Moderate Severity IDH Differentiation Syndrome  
Based  on presence of at least 2 of the below listed factors, in absence of signs of severe IDH DS  
• Unexplained fever ≥38○C (100.4○F)  
• New or worsened peripheral edema without definitive etiology , or rapid weight gain ( e.g., > 5 kg/11 
pounds) 
• Rash of unknown origin 
• New or worsened bone pain or arthralgia without other clear etiology 
• Lymphadenopathy  
• Increase in serum creatinine (e.g., > 2-fold from baseline) 
Conditions that may co- occur with differentiation syndrome  
• Commonly co-occur: Leukocytosis in the absence of an infectious process 
• Infrequently co- occur: Laboratory Tumor Lysis Syndrome (TLS), or TLS associated with increased 
serum creatinine level, in settings of rapidly increasing blood cell count (leukocytosis)  
• Rarely co -occur: Coagulopathy in the setting of increased blood cell count  
Management of subjects with suspected IDH inhibitors -differentiation syndrome  
Conditions consistent with signs and symptoms of IDH DS  but refractory to treatment for the initially 
suspected cause(s), or that worsen within the first 48 hours after treatment initiation, should be managed 
as potential IDH DS . 
It is recommended that the measures indicated below are undertaken at the earliest manifestations of 
suspected IDH DS . 
• Patients with severe or rapidly progressing IDH DS should be hospitalized for continued 
observation 
• In case of uncertainty with the diagnosis, e.g. presence of less specific symptoms of moderate 
severity IDH DS, patien ts should be closely monitored, as condition may rapidly exacerbate 
• Corticosteroids should be promptly initiated at a suggested dose 10 mg of dexamethasone IV every 
12 hours until complete resolution of IDH DS, after which the dose can be progressively reduced 
in the next few days or weeks  
• The study drug may be withheld at the investigator’s discretion. Due to long half -life of the 
IDH-inhibitors, treatment interruption may not immediately reverse symptoms of IDH DS.  
Potential for drug -drug interaction between IDH inhibitor and treatments initiated for management 
of IDH DS should be considered, when making decisions about study drug treatment interruption.  If interrupted, study drug treatment may be reinitiated at the original or reduced dose once  the sign s 
and symptoms resolve and the subject’s clinical condition improves.  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 73 of 77   10 Nov 2021  
Confidential  
• If renal dysfunction or severe pulmonary symptoms requiring intubation or ventilator support 
persist for more than 48 hours after initiation of systemic corticosteroids, interrupt enasidenib 
treatment until signs and symptoms are no longer severe 
• In subjects with elevated WBC, prompt initiation of hydroxyurea is suggested, as per standard local 
practices (e.g., dose of 2 to 3g PO twice or three times daily for WBC >30x109/L) 
• In cases of severe leukocytosis, use of leukapheresis may be appr opriate  
• For substantial fluid accumulation, initiation of furosemide may be appropriate, as per local 
standard practice  
• Pericardial effusion - a less common symptom of IDH DS - can be life threatening condition 
requiring urgent intervention 
• Subjects with increasing serum creatinine levels should be evaluated for TLS  
• Subjects experiencing rapid increase in peripheral blood cells should be monitored for disseminated intravascular coagulopathy and hemorrha ges 
• Imaging techniques such as standard or high -resolution CT or chest X -ray are useful in establishing 
a diagnosis of IDH DS. However, chest X -ray is less sensitive in detecting early radiological signs 
of IDH DS  associated changes.  
Immediate communicatio n with the Study Co- Chairs  is encouraged for guidance regarding treatment.  
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 74 of 77   10 Nov 2021  
Confidential  
34.5  APPENDIX E:  EASTERN COOPERATIVE ONCOLOGY GROUP 
(ECOG) PERFORMANCE SCORE RATINGS  
 
At each clinic visit after the screening visit, the investigator will assess each subject’s ECOG 
performance status according to the following scale:  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary natur e, e.g., light house-work, office work 
2 Ambulatory and capable of all self -care but unable to carry out any work activities.  Up and about 
more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care.  Totally confined to bed or chair 
5 Dead  
 
 
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 75 of 77   10 Nov 2021  
Confidential  
34.6  APPENDIX F: MYELOFIB ROSIS SYMPTOM ASSESSMENT FORM 
(MF -SAF) V4.0  
Instructions:  The following questions refer to symptoms that you may experience as  a result of your 
myelofibrosis.  Please read through and complete the questions below.  There are no right or wrong 
answers.  Please select the answer that best applies to you.  
1. During the past 7 days, how severe was your worst fatigue (weariness, tir edness)?  
0 1 2 3 4 5 6 7 8 9 10 
Absent          Worst Imaginable  
 
2. During the past 7 days, how severe were your worst night sweats (or feeling hot or flushed)?  
0 1 2 3 4 5 6 7 8 9 10 
Absent          Worst Imaginable  
 
3. During the past 7 days, how severe was your worst itching?  0 1 2 3 4 5 6 7 8 9 10 
Absent          Worst Imaginable  
 
4. During the past 7 days, how severe was your worst abdominal discomfort (feel pressure or bloating)?  
0 1 2 3 4 5 6 7 8 9 10 
Absent          Worst Imaginable  
 
5. During the past 7 days, how severe was the worst pain under your ribs on your left side?  
0 1 2 3 4 5 6 7 8 9 10 
Absent          Worst Imaginable  
 6. During the past 7 days, what was the worst feeling of fullness you had after beginning to eat?  
0 1 2 3 4 5 6 7 8 9 10 
Absent          Worst Imaginable  
 
7. During the past 7 days, how severe was your worst bone pain (not joint or arthritis pain)?  
0 1 2 3 4 5 6 7 8 9 10 
Absent          Worst Imaginable  
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 76 of 77   10 Nov 2021  
Confidential  
34.7  APPENDIX G: NEW YORK  HEART ASSOCIATION (NYHA) CLASS 
III OR  IV CONGESTIVE HEART  FAILURE  
 
 
Class  Patient  Symptoms  
I(Mild)  No limitation  of physical  activity.  Ordinary  physical  activity  does not cause  undue  fatigue,  
palpitation,  or dyspnea  (shortness  of breath).  
II(Mild)  Slight  limitation  of physical  activity.  Comfortable  at rest, but ordinary  physical  activity  results  
in fatigue,  palpitation,  or dyspnea.  
III(Moderate)  Marked  limitation  of physical  activity.  Comfortable  at rest, but less-than- ordinary  activity  
causes  fatigue,  palpitation,  or dyspnea.  
IV(Severe)  Unable  to carry  out any physical  activity  without  discomfort.  Symptoms  of cardiac 
insufficiency  at rest. If any physical  activity  is undertaken,  discomfort  is increased.  
Source: Dolgin  M, Fox AC, Devereaux  RB. Nomenclature  and criteria  for diagnosis  of diseases  of the heart  and great  vessels.  9th 
ed. Boston:  Little  Brown  and Company;  1994  p.253-256. 
 
  
A Phase II Open -label Study of Combined Ruxolitinib and Enasidenib 
in Patients with Accelerated/Blast -phase Myeloproliferative Neoplasm or Chronic-
phase Myelofibrosis with  an IDH2 Mutation 
(Myeloproliferative Neoplasms Research  Consortium [MPN -RC] 119)  
Amendment 2    Page 77 of 77   10 Nov 2021  
Confidential  
34.8 APPENDIX H: FDA MEDWATCH FORM  
https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048334.pdf  
 
 
 
 